



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/815,242	03/21/2001	Robert Haselbeck	ELITRA.011A	7191
210	7590	11/17/2004	EXAMINER	
MERCK AND CO INC P O BOX 2000 RAHWAY, NJ 070650907			GIBBS, TERRA C	
			ART UNIT	PAPER NUMBER

1635

DATE MAILED: 11/17/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/815,242

Applicant(s)

HASELBECK ET AL.

Examiner

Terra C. Gibbs

Art Unit

1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 29 December 2003.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-102 is/are pending in the application.
- 4a) Of the above claim(s) 1-11, 13-30, 32-44 and 70 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 12, 31, 45-69 and 71-102 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>November 17, 2003</u> . | 6) <input checked="" type="checkbox"/> Other: <u>Attached sequence hit list</u> .       |

### **DETAILED ACTION**

This Office Action is a response to Applicant's Amendment and Remarks filed September 28, 2004.

Claims 1-102 are pending in the instant application. Claims 1-11, 13-30, 32-44 and 70 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement on June 30, 2002.

Claims 12, 31, 45-69, and 71-102 have been examined on the merits.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

### ***Change in Power of Attorney***

Applicant's change in Power of Attorney filed September 28, 2004 is acknowledged.

### ***Specification***

The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01. Appropriate correction is required.

The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any error of which Applicant may become aware in the disclosure.

***Withdrawal of Finality***

Applicants received a Final Office Action mailed March 22, 2004. After careful reconsideration of the claims, the Examiner has decided to reopen prosecution of the instant application because 35 U.S.C. 112, first paragraph issues were not raised by the Examiner earlier during prosecution. The Final Office Action mailed March 22, 2004, is vacated and a new Non-Final Office Action on the merits follows.

***Response to Arguments***

In the previous Office Action mailed March 22, 2004, claims 12, 31, 45-69 and 71-102 were rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

In response to this rejection, Applicants argue that neither the independent claims, nor the claims dependent thereon, are drawn to an invention that encompasses “*any gene* product in a cell whose activity is reduced by an antisense, thereby producing a sensitized cell”, as argued by the Examiner. Applicants contend that the claims are drawn to providing an antisense nucleic acid to reduce the activity or amount of a gene product whose activity or amount is reduced by an antisense comprising a nucleotide sequence having a specific sequence identification number, namely elected SEQ ID NO:1463. Applicants also argue that the specification describes several yphC genes from a variety of cells, the gene products encoded by those genes, and antisense nucleic acids that are capable of reducing the activity or amount of such yphC gene product.

Art Unit: 1635

Applicants argue that this description is in accordance with the Written Description Guidelines (66 FR 1099, January 5, 2001).

Applicant's arguments have been fully considered and are found persuasive by the Examiner. Specifically, the Examiner agrees that the claims are drawn to providing an antisense nucleic acid to reduce the activity or amount of a gene product whose activity or amount is reduced by an antisense comprising a nucleotide sequence having a specific sequence identification number, namely elected SEQ ID NO:1463. The Examiner has also been persuaded by Applicants Remarks regarding that the specification describes several yphC genes from a variety of cells, the gene products encoded by those genes, and antisense nucleic acids that are capable of reducing the activity or amount of such yphC gene product. Therefore, in view of Applicants arguments, the 35 U.S.C. 112, first paragraph rejection against claims 12, 31, 45-69 and 71-102 for written description is withdrawn.

### *Claim Rejections - 35 USC § 112*

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 12, 31, 45-69, and 71-102 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. **This is a written description rejection.**

Applicant is referred to the interim guidelines on written description published on December 21, 1999 in the Federal Register at Volume 64, Number 244, pp. 71427-71440.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed.” (see page 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invention what is claimed.” (See Vas-Cath at page 1116).

The specification provides adequate written description for a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid comprising SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing sensitized bacterial cells, as described in claims 101 and 102.

However, the claims are so broad as to encompass producing *any* type of sensitized cell, including cells from higher organisms. A sequence search of the relevant art reveals that SEQ ID NO:1463 is an antisense nucleic acid 100% complementary to the YphC gene of the *Staphylococcus aureus* bacterium (see attached sequence hit list). It is noted that the prior art hit list reflects only microbial cells, and not higher organisms. Applicant’s arguments, filed December 29, 2003 describe the YphC gene as being required for proliferation of *Staphylococcus auerus* (see Applicants Remarks, page 2, first paragraph). It appears that the prior art and Applicants Remarks filed December 29, 2003 describe that SEQ ID NO:1463 will only target and sensitize bacterial cells, as opposed to *any* cell, including cells from higher

Art Unit: 1635

organisms as broadly claimed. The species specifically disclosed is not representative of the genus because the genus is highly variant (e.g. protista cell, bacterial cell, fungal cell, plant cell, animal cell, etc.). Given the broadness of the sensitized cell encompassed in the claimed methods, the disclosure of the specification provides insufficient written description to support the genus encompassed by the claim.

Claims 31, 45-69, 71-84, and 102 are drawn to a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid having at least 97%, 95%, 90% 85%, 80%, 70% sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized cell.

The specification as filed teaches providing a sublethal level of an antisense nucleic acid comprising SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized bacterial cell, as described in claims 101 and 102. The specification as filed fails to adequately describe providing a sublethal level of an antisense nucleic acid having at least 97%, 95%, 90% 85%, 80%, 70% sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized cell.

With limited disclosure provided by the specification, the skilled artisan cannot envision those antisense nucleic acids with varying degrees of sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized cell. This functional limitation itself is not sufficient to provide a structure/function relationship for meeting the written description requirement because it is not clear what structure

Art Unit: 1635

the antisense nucleic acids with varying degrees of sequence identity to SEQ ID NO:1463 would have by the recitation of the functionality alone, “reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized cell”. The specification provides no guidance in this regard. The claimed invention as a whole is not adequately described if the claims require essential or critical elements which are not adequately described in the specification. Possession may be shown by actual reduction to practice, clear depiction of the invention in a detailed drawing, or by describing the invention with sufficient relevant identifying characteristics such that a person skilled in the art would recognize that the inventor had possession of the claimed invention. *Pfaff vs. Electronics, Inc.*, 48 USPQ2d, 1641, 1646 (1998).

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481, 1483. In *Fiddes*, claims directed to mammalian FGF’s were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

Therefore, only a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid comprising SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing sensitized bacterial cells, as described in claims 101 and 102, meets the written description provision of 35 U.S.C. 112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. 112 is severable from its enablement provision (see page 1115).



Art Unit: 1635

Claims 12, 31, 45-69, and 71-102 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid comprising SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized bacterial cell as described in claims 101 and 102, does not reasonably provide enablement for a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid comprising SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing *any* sensitized cell, as recited in claims 12 and 85-100, or a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid having at least 97%, 95%, 90%, 85%, 80%, 70% sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized cell, as recited in claim 31 and 45-84. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or the invention commensurate in scope with these claims.

**This is a scope enablement rejection.**

The following factors have been considered in formulating this rejection (*In re Wands*, 858F.2d 731, 8 USPQ2d 1400 (Fed. Cir. 1988)): the breadth of the claims, the nature of the invention, the state of the prior art, the relative skill of those in the art, the predictability or unpredictability of the art, the amount of direction or guidance presented, the presence or absence of working examples of the invention, and the quantity of experimentation necessary.

Art Unit: 1635

Claims 12 and 85-101 are drawn to a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid comprising SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing *any* sensitized cell. Claims 31, 45-84, and 102 are drawn to a method for screening a candidate compound for the ability to reduce cellular proliferation comprising providing a sublethal level of an antisense nucleic acid having at least 97%, 95%, 90%, 85%, 80%, 70% sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized cell.

To begin, as per the 35 U.S.C. 112 first paragraph rejection above for written description, there is no direction or guidance in the instant specification as filed for producing *any* sensitized cell, other than those bacterial cells described in claims 101 and 102. For example, what kind of cell will have the target for SEQ ID NO:1463 encoding a gene product whose activity or amount is reduced such that the cell is sensitized? A sequence search of the relevant art reveals that SEQ ID NO:1463 is an antisense nucleic acid 100% complementary to the YphC gene of the *Staphylococcus aureus* bacterium (see attached sequence hit list). It is noted that the prior art hit list reflects only microbial cells, and not higher organisms. Applicant's arguments, filed December 29, 2003 describe the YphC gene as being required for proliferation of *Staphylococcus auerus* (see Applicants Remarks, page 2, first paragraph). It appears that the prior art and Applicants Remarks filed December 29, 2003 describe that SEQ ID NO:1463 will only target and sensitize bacterial cells, as opposed to *any* cell, including cells from higher organisms as broadly claimed. Significant trial and error experimentation would be required to practice the method over the scope claimed since the skilled artisan would need to determine

Art Unit: 1635

what kind of cell (e.g. protista, bacterial, fungal, plant, animal, etc.) will have the target for SEQ ID NO:1463 encoding a gene product whose activity or amount is reduced such that the cell is sensitized, and serve to screen for candidate compounds which inhibit proliferation. There is no predictability whether *any* kind of sensitized cell can be produced by the methods recited, other than those bacterial cells described in claims 101 and 102.

Second, and as per the 35 U.S.C. 112 first paragraph rejection above for written description, there is no direction or guidance in the instant specification as filed for providing a sublethal level of an antisense nucleic acid having at least 97%, 95%, 90%, 85%, 80%, 70% sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product required for cellular proliferation, thereby producing a sensitized bacterial cell. The specification teaches SEQ ID NO:1463, which reduces the activity of a gene product, thereby producing a sensitized bacterial cell as described in claims 101 and 102. The specification as filed fails to adequately describe those antisense nucleic acids with varying degrees of sequence identity to SEQ ID NO:1463, which produces a sensitized cell. Because functionality alone as recited in the instant claims does not elucidate the structure (e.g. nucleotide sequence) it would require undue experimentation to practice the invention as claimed. The quantity of experimentation required to practice the invention as claimed would involve the determination of those antisense nucleic acids with varying degrees of sequence identity to SEQ ID NO:1463, which reduces the activity of a gene product, thereby producing a sensitized cell. To practice the claimed methods, the skilled artisan would need to undergo undue trial and error experimentation, beyond the teachings and guidance of the specification to practice the methods, over the scope claimed.

Art Unit: 1635

Therefore, in view of the unpredictability of the art, the breadth of the claims, and the lack of guidance provided by the specification, one of ordinary skill in the art at the time of the invention would have required an undue amount of experimentation to make and use the claimed invention over the scope claimed.

***Conclusion***

No claims are allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Terra C. Gibbs whose telephone number is (571) 272-0758. The examiner can normally be reached on M-F 9:00-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John L. LeGuyader can be reached on (571) 272-0760. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

tcg  
November 4, 2004

JOHN L. LEGUYADER  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600

genCore version 5.1.6  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 12, 2003, 17:16:39 : Search time 129.915 Seconds  
(without alignments)  
8041.284 Million cell updates/sec

Title: US-09-815-242-1463

Perfect score: 387

Sequence: 1 gatctcttccttcaccca.....ttcacctgaagaataaacac 387

Scoring table: IDENTITY\_NUC

Gapop 10.0, Gapext 1.0

Searched: 252756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.\*  
2: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.\*  
3: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.\*  
4: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.\*  
5: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.\*  
6: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.\*  
7: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.\*  
8: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.\*  
9: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.\*  
10: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.\*  
11: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.\*  
12: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.\*  
13: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.\*  
14: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.\*  
15: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.\*  
16: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.\*  
17: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.\*  
18: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.\*  
19: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.\*  
20: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.\*  
21: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.\*  
22: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.\*  
23: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.\*  
24: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.\*  
25: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2003.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length DB ID	Description
1	387	100.0	387 23 AAS48886	Staphylococcus aur
C 2	387	100.0	1311 22 AAF86461	Staphylococcus aur
C 3	387	100.0	1311 23 AAS54997	Staphylococcus aur
C 4	383.8	99.2	1305 23 AAS51646	Staphylococcus aur
C 5	383.8	99.2	1311 23 AAS54865	Staphylococcus aur
C 6	327	84.5	3621 18 AAV74669	Staphylococcus aur
C 7	295	76.2	372 23 AAS50706	Staphylococcus aur
C 8	262.2	67.6	1332 24 ABN90883	Staphylococcus epi

9 262.2 57.8 3269 22 AAS4708  
10 234 60.5 298 23 AAS50205  
11 234 60.5 298 23 AAS50723  
12 205.8 53.2 319630 24 ABO67194  
13 205.8 53.2 2944528 24 ABA03041  
14 205.8 53.2 3011208 24 ABO69245  
15 174.4 45.1 1311 24 ABK75008  
16 162.6 42.0 1308 24 ABN68458  
17 162.6 42.0 2365589 24 ABA90521  
18 160.4 41.4 1308 24 ABN68457  
19 160.4 41.4 2155561 24 ABN71527  
20 153 39.5 1311 21 AAS4516  
21 151.4 39.1 1308 25 ABK07474  
22 151.4 39.1 1311 21 ABK291825  
23 151.4 39.1 5066 19 AAV5212  
24 151.4 39.1 2162598 25 AAS56454  
25 146 37.7 246 23 AAS45268  
26 101 26.1 960 22 AAS3683  
27 89.4 23.1 1512 23 AAS5517  
28 89.4 23.1 11574 22 AAS46244  
29 86 22.2 157 23 AAS50894  
30 84.4 21.8 1512 22 AAF94379  
31 84.4 21.8 1512 24 AAF64943  
32 84.4 21.8 1515 23 AAS53235  
33 83.8 21.7 1473 23 AAS55968  
34 80.6 20.8 640681 24 ABA97787  
35 80.2 20.7 1830121 17 AAT2063  
36 73.2 18.9 13370 19 AAZ9377  
37 73 18.9 33140 22 AAF28336  
38 69.8 18.0 1557 25 ACA00899  
39 69.8 18.0 1557 22 AAF65542  
40 69.8 18.0 349980 22 AAF65528  
41 69.8 18.0 349980 22 AAF65529  
42 64 16.5 25360 22 AAF68314  
43 64 16.5 25360 22 AAF68317  
44 62 16.0 580073 18 AAT58840  
45 61.4 15.9 78845 21 AAA81463

## ALIGNMENTS

### RESULT 1

AAS48886  
ID AAS48886 standard; DNA: 387 BP.

AC AAS48886;

DT 13-FEB-2002 (first entry)

DE Staphylococcus aureus cellular proliferation inhibitory sequence #110.

KW Antisense; ss: prokaryotic cellular proliferation;

KW antibiotic; antibacterial; drug design.

OS Staphylococcus aureus.

PN WO200170955-A2.

PD 27-SEP-2001.

PF 21-MAR-2001; 2001WO-US09180.

PR 21-MAR-2000; 2000US-191078P.

PR 23-MAY-2000; 2000US-206848P.

PR 26-MAY-2000; 2000US-207777P.

PR 27-OCT-2000; 2000US-242578P.

PR 27-NOV-2000; 2000US-253625P.

PR 22-DEC-2000; 2000US-257931P.

PR 16-FEB-2001; 2001US-269108P.

XX (ELIT-) ELITRA PHARM INC.

XX

Applicants Copy Hit List  
Sequence Hit List

PI Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;  
 PI Yamamoto RT, Xu HH;  
 DR WPI: 2001-611495/70.  
 XX New polynucleotides for the identification and development of  
 PT antibiotics, comprise sequences of antisense nucleic acids -  
 XX  
 PS Claim 1: Seq ID No 1463; 511pp; English.  
 XX  
 CC The invention relates to antisense inhibitors of genes essential to  
 CC prokaryotic cellular proliferation, their use in identifying the  
 CC genes, themselves and the encoded proteins. The prokaryotes used are  
 CC Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella  
 CC pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The  
 CC invention is also useful for the identification of potential new targets  
 CC for antibiotic development. The antisense nucleic acids can also be used  
 CC to identify proteins used in proliferation, to express these proteins,  
 CC and to obtain antibodies capable of binding to the expressed proteins.  
 CC The proteins can be used to screen compounds in rational drug discovery  
 CC programmes. The antisense nucleic acid sequence is also useful to screen  
 CC for homologous nucleic acids which are required for cell proliferation in  
 CC a wide variety of organisms. The present sequence is an antisense  
 CC oligonucleotide of the invention.  
 CC Note: The sequence data for this patent did not form part  
 CC of the printed specification, but was obtained in electronic  
 CC format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences.

XX SQ Sequence 387 BP; 122 A; 91 C; 53 G; 121 T; 0 other;

Query Match 100.0%; Score 387; DB 23; Length 387;  
 Best Local Similarity 100.0%; Pred. No. 1.2e-98;  
 Matches 387; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCTTCTCTCTTCCACCAATGAGAAACACTGCTTACCAAGTCACCAACCTA 60  
 DB 1 GATCTTCTCTCTTCCACCAATGAGAAACACTGCTTACCAAGTCACCAACCTA 60  
 QY 61 AACCATGTGACCTGATATGGATACGGTTACCAAAATCCTAATGATAGAAATCATACA 120  
 DB 61 AACCATGTGACCTGATATGGATACGGTTACCAAAATCCTAATGATAGAAATCATACA 120  
 QY 121 CGCTGTGACCATTTCCATATTTACTTGTGTTAAACCGCTAATACGCGGTTTTTTAG 180  
 DB 121 CGCTGTGACCATTTCCATATTTACTTGTGTTAAACCGCTAATACGCGGTTTTTTAG 180  
 QY 181 ATTTGTATAAAATTTGACGACCATTTTCATCGCTTTGTGTCATCTTCACGCGTTAA 240  
 DB 181 ATTTGTATAAAATTTGACGACCATTTTCATCGCTTTGTGTCATCTTCACGCGTTAA 240  
 QY 241 CCATATAAATAATACATCGCTTCATCTATGCGGATTTTCGCTCGCGCTCTAATTTGTG 300  
 DB 241 CCATATAAATAATACATCGCTTCATCTATGCGGATTTTCGCTCGCGCTCTAATTTGTG 300  
 QY 301 TTGGAATGGTGCATACCAATTTCAATACCACTGCTATCAATAATATTGAAATCATGTG 360  
 DB 301 TTGGAATGGTGCATACCAATTTCAATACCACTGCTATCAATAATATTGAAATCATGTG 360  
 QY 361 TTAACCATTCACCTGAAGAATAAATAC 387  
 DB 361 TTAACCATTCACCTGAAGAATAAATAC 387

## RESULT 2

AAF86461/c  
 ID AAF86461 standard; DNA; 1311 BP.  
 XX  
 AC AAF86461;  
 XX  
 DT 26-JUN-2001 (first entry)  
 XX

DE Staphylococcus aureus yphC coding sequence.  
 XX yphC; antimicrobial; cytostatic; antiulcer; microbial infection;  
 KW gene therapy; vaccine; gastrointestinal carcinoma; gastric ulcer;  
 KW gastritis; ds.  
 XX Staphylococcus aureus.  
 OS  
 FH Key Location/Qualifiers  
 FT CDS 1..1311  
 FT /\*tag= a  
 FT /product= "Staphylococcus aureus yphC protein"  
 XX  
 PN W0200123418-A1.  
 XX  
 PD 05-APR-2001.  
 XX  
 PF 19-SEP-2000; 2000MO-US25566.  
 XX  
 PR 28-SEP-1999; 99US-0406968.  
 XX  
 PA (SMIK ) SMITHKLINE BEECHAM CORP.  
 PA (SMIK ) SMITHKLINE BEECHAM PLC.  
 XX  
 PI Zalacain M, Biswas S, Burnham MKR, Sylvester D, Mcdevitt D;  
 PI Mathie TB;  
 PI  
 DR WPI: 2001-308138/32.  
 DR P-PSDB: AAB82089.  
 XX  
 XX Novel yphC polypeptides of Staphylococcus aureus useful for diagnosing  
 PT and treating microbial infections, especially infection by  
 PT Staphylococcus aureus and Helicobacter pylori -  
 XX  
 PS Claim 2: Page 2-3; 41pp; English.  
 XX  
 CC The present sequence is the gene encoding yphC polypeptide of  
 CC Staphylococcus aureus. The yphC coding sequence and protein are useful  
 CC for treating and diagnosing microbial infections such as infection caused  
 CC by S.aureus and Helicobacter pylori. In addition, the yphC coding  
 CC sequence and protein are useful for treating diseases such as  
 CC R.pylori-induced cancers, e.g. gastrointestinal carcinoma, gastric  
 CC ulcers, and gastritis. The present sequence was obtained from a library  
 CC of clones of chromosomal DNA of S.aureus in E.coli. The sequencing data  
 CC from two or more clones comprising overlapping S.aureus DNAs was used to  
 CC construct the present contiguous DNA sequence.  
 XX  
 SQ Sequence 1311 BP; 451 A; 184 C; 278 G; 398 T; 0 other;

Query Match 100.0%; Score 387; DB 22; Length 1311;  
 Best Local Similarity 100.0%; Pred. No. 1.8e-98;  
 Matches 387; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCTTCTCTCTTCCACCAATGAGAAACACTGCTTACCAAGTCACCAAGCTA 60  
 DB 508 GATCTTCTCTCTTCCACCAATGAGAAACACTGCTTACCAAGTCACCAAGCTA 449  
 QY 61 AACCATGTGACCTGATATGGATACGGTTACCAAAATCCTAATGATAGAAATCATACA 120  
 DB 448 AACCATGTGACCTGATATGGATACGGTTACCAAAATCCTAATGATAGAAATCATACA 389  
 QY 121 CGCTGTGACCATTTCCATATTTACTTGTGTTAAACCGCTAATACGCGGTTTTTTAG 180  
 DB 388 CGCTGTGACCATTTCCATATTTACTTGTGTTAAACCGCTAATACGCGGTTTTTTAG 329  
 QY 181 ATTTGTATAAAATTTGACGACCATTTTCATCGCTTTGTGTCATCTTCACGCGTTAA 240  
 DB 328 ATTTGTATAAAATTTGACGACCATTTTCATCGCTTTGTGTCATCTTCACGCGTTAA 269  
 QY 241 CCATATAAATAATACATCGCTTTCATCTATGCGGATTTTCGCTCGCTCTAATTTGTG 300  
 DB 268 CCATATAAATAATACATCGCTTTCATCTATGCGGATTTTCGCTCGCTCTAATTTGTG 209

QY 301 TTGGAATGGTGCATCACCACCAATTTCAATACACCTGATCAATAATATTGAATCATGTG 360  
 Db 208 TTGGAATGGTGCATCACCACCAATTTCAATACACCTGATCAATAATATTGAATCATGTG 149  
 QY 361 TTACCAATTCACCTGAGCAATAATATAC 387  
 Db 148 TTACCAATTCACCTGAGCAATAATATAC 122

## RESULT 3

AAS54997/c  
 ID AAS54997 standard; DNA; 1311 BP.

AC AAS54997;  
 XX

DT 13-FEB-2002 (first entry)  
 XX

DE Staphylococcus aureus DNA for cellular proliferation protein #1309.  
 XX

KW Antisense; ds: prokaryotic cellular proliferation gene;  
 XX

KW Antibiotic; antibacterial; drug design.  
 XX

OS Staphylococcus aureus.  
 XX

XX WO200170955-A2.  
 PN

XX 27-SEP-2001.  
 PD

XX 21-MAR-2001; 2001WO-US09180.  
 PF

XX 21-MAR-2000; 2000US-191078P.  
 PR

XX 23-MAY-2000; 2000US-206848P.  
 PR

XX 26-MAY-2000; 2000US-207727P.  
 PR

XX 23-OCT-2000; 2000US-242578P.  
 PR

XX 27-NOV-2000; 2000US-253625P.  
 PR

XX 22-DEC-2000; 2000US-257931P.  
 PR

XX 16-FEB-2001; 2001US-269308P.  
 PR

XX (ELIT-) ELITRA PHARM INC.  
 PA

XX Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;  
 PI Yamamoto RT, Xu HH;

XX WPI: 2001-611495/70.  
 DR

XX P-PSDB; AAU37138.  
 DR

XX New polynucleotides for the identification and development of  
 PT antibiotics, comprise sequences of antisense nucleic acids -

XX Claim 27; Seq ID No 8634; 51pp; English.  
 PS

XX The invention relates to antisense inhibitors of genes essential to  
 CC prokaryotic cellular proliferation, their use in identifying the  
 CC genes, their use in the discovery of novel antibiotics, the essential  
 CC genes themselves and the encoded proteins. The prokaryotes used are  
 CC *Escherichia coli*, *Staphylococcus aureus*, *Salmonella typhi*, *Klebsiella*  
 CC *pneumoniae*, *Pseudomonas aeruginosa* and *Enterococcus faecalis*. The  
 CC invention is also useful for the identification of potential new targets  
 CC for antibiotic development. The antisense nucleic acids can also be used  
 CC to identify proteins used in proliferation, to express these proteins,  
 CC and to obtain antibodies capable of binding to the expressed proteins.  
 CC The proteins can be used to screen compounds in rational drug discovery  
 CC programmes. The antisense nucleic acid sequence is also useful to screen  
 CC for homologous nucleic acids which are required for cell proliferation in  
 CC a wide variety of organisms. The present sequence encodes an  
 CC essential prokaryotic cellular proliferation protein.  
 CC Note: the sequence data for this patent did not form part  
 CC of the printed specification, but was obtained in electronic  
 CC format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences.

XX Sequence 1311 BP: 452 A; 184 C; 278 G; 397 T; 0 other;  
 SQ

Query Match 100.0%; Score 387; DB 23; Length 1311;  
 Best Local Similarity 100.0%; Pred. No. 1.8e-98;  
 Matches 387; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCTTCTCTCTTCCACCAAAATGAGAAACAACTGCTATCAAGTCACCAAGACCTA 60  
 Db 508 GATCTTCTCTCTTCCACCAAAATGAGAAACAACTGCTATCAAGTCACCAAGACCTA 449  
 QY 61 AACCATGTGACCTGATATCGGATACGGTTCAGCAAACTCTTAATAGAAATCATACA 120  
 Db 448 AACCATGTGACCTGATATCGGATACGGTTCAGCAAACTCTTAATAGAAATCATACA 389  
 QY 121 CGTCTGTACGCATTTCCATATATTCTACTTTGTTAACGGCTAATACGACCGTTTTAG 180  
 Db 388 CGTCTGTACGCATTTCCATATATTCTACTTTGTTAACGGCTAATACGACCGTTTTAG 329  
 QY 181 ATTTGTATATAAATTTGAGCGACCATTTTCATCGCTTTTGTGTCATCTTCCACGACGTTAA 240  
 Db 328 ATTTGTATATAAATTTGAGCGACCATTTTCATCGCTTTTGTGTCATCTTCCACGACGTTAA 269  
 QY 241 CCATAAAAAATAATAACATCGCTTTCATCTATGCGGATTTCTGCGCTCTTAATTTGTG 300  
 Db 268 CCATAAAAAATAATAACATCGCTTTCATCTATGCGGATTTCTGCGCTCTTAATTTGTG 209  
 QY 301 TTGGAATGGTGCATCACCACCAATTTCAATACACCTGATCAATAATATTGAATCATGTG 360  
 Db 208 TTGGAATGGTGCATCACCACCAATTTCAATACACCTGATCAATAATATTGAATCATGTG 149  
 QY 361 TTACCAATTCACCTGAGCAATAATATAC 387  
 Db 148 TTACCAATTCACCTGAGCAATAATATAC 122

## RESULT 4

AAS51646/c  
 ID AAS51646 standard; DNA; 1305 BP.

XX AAS51646;  
 AC

XX 13-FEB-2002 (first entry)  
 DT

XX Staphylococcus aureus DNA for cellular proliferation protein #63.  
 DE

XX Antisense; ds: prokaryotic cellular proliferation gene;  
 KW antibiotic; antibacterial; drug design.

XX Staphylococcus aureus.  
 OS

XX WO200170955-A2.  
 PN

XX 27-SEP-2001.  
 PD

XX 21-MAR-2001; 2001WO-US09180.  
 PF

XX 21-MAR-2000; 2000US-191078P.  
 PR

XX 23-MAY-2000; 2000US-206848P.  
 PR

XX 26-MAY-2000; 2000US-207727P.  
 PR

XX 23-OCT-2000; 2000US-242578P.  
 PR

XX 27-NOV-2000; 2000US-253625P.  
 PR

XX 22-DEC-2000; 2000US-257931P.  
 PR

XX 16-FEB-2001; 2001US-269308P.  
 PR

XX (ELIT-) ELITRA PHARM INC.  
 PA

XX Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;  
 PI Yamamoto RT, Xu HH;

XX WPI: 2001-611495/70.  
 DR

XX P-PSDB; AAU33787.  
 DR

XX New polynucleotides for the identification and development of  
 PT antibiotics, comprise sequences of antisense nucleic acids -

XX

PS Claim 27; Seq ID No 4228; 511pp; English.

XX The invention relates to antisense inhibitors of genes essential to  
CC prokaryotic cellular proliferation, their use in identifying the  
CC genes, their use in the discovery of novel antibiotics, the essential  
CC genes themselves and the encoded proteins. The prokaryotes used are  
CC Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella  
CC pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The  
CC invention is also useful for the identification of potential new targets  
CC for antibiotic development. The antisense nucleic acids can also be used  
CC to identify proteins used in proliferation, to express these proteins,  
CC and to obtain antibodies capable of binding, to the expressed proteins.  
CC The proteins can be used to screen compounds in rational drug discovery  
CC programmes. The antisense nucleic acid sequence is also useful to screen  
CC for homologous nucleic acids which are required for cell proliferation in  
CC essential prokaryotic cellular proliferation protein.  
CC Note: The sequence data for this patent did not form part  
CC of the printed specification, but was obtained in electronic  
CC format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences.

XX Sequence 1305 BP; 447 A; 181 C; 277 G; 400 T; 0 other;

Query Match 99.2%; Score 383.8; DB 23; Length 1305;  
Best Local Similarity 99.5%; Pred. No. 1.4e-97;  
Matches 385; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GATCTTCTCTCTTACCAAAATGAGAACTGTCATCTAACAAGTCACCAAGACCTA 60  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
508 GATCTTCTCTCTTACCAAAATGAGAACTGTCATCTAACAAGTCACCAAGACCTA 449  
Qy 61 AACCATGTGACCTGATATCGGATACGGTTCCACCAATCCTTAATGAATAGATACATA 120  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
448 AACCATGTGACCTGATATCGGATACGGTTCCACCAATCCTTAATGAATAGATACATA 389  
Qy 121 CGTCTGACGATTCCTCATATCTACTTTGTAACGGCTTAATGACCGGTTTTTAG 180  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
388 CGTCTGACGATTCCTCATATCTACTTTGTAACGGCTTAATGACCGGTTTTTAG 329  
Qy 181 ATTTGTATAAATTTGAGCGCATTTTCATCGCTTTGTGTCATCTTACCGACCGTTAA 240  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
328 ATTTGTATAAATTTGAGCGCATTTTCATCGCTTTGTGTCATCTTACCGACCGTTAA 269  
Qy 241 CCATAAAATAAATTAACATCCGCTTCATCTATGGGATTTCTGCTGGCTCTAATTTGTG 300  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
268 CCATAAAATAAATTAACATCCGCTTCATCTATGGGATTTCTGCTGGCTCTAATTTGTG 209  
Qy 301 TTTGGAATGGTGATCACCACCAATTTCAATACCACTGTATCAATAATTTGAATCATGTG 360  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
208 TTTGGAATGGTGATCACCACCAATTTCAATACCACTGTATCAATAATTTGAATCATGTG 149  
Qy 361 TTAACCATTCACCTGAGATAAATAC 387  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
148 TTAACCATTCACCTGAGATAAATAC 122

RESULT 5  
AAS54865/C  
ID AAS54865 standard; DNA: 1311 BP.  
XX AAS54865;  
AC AAS54865;  
XX  
DT 13-FEB-2002 (first entry)  
XX Staphylococcus aureus DNA for cellular proliferation protein #1177.  
DE  
XX Antisense; ds; prokaryotic cellular proliferation gene;  
KW antibiotic; antibacterial; drug design.  
XX  
OS Staphylococcus aureus.  
XX  
PN WO200170955-A2.

XX 27-SEP-2001.

PD 21-MAR-2001; 2001WO-US09180.

XX 21-MAR-2000; 2000US-191078P.

PF 23-MAY-2000; 2000US-206848P.

XX 28-MAY-2000; 2000US-207727P.

PR 23-OCT-2000; 2000US-242578P.

PR 27-NOV-2000; 2000US-253625P.

PR 22-DEC-2000; 2000US-257931P.

PR 16-FEB-2001; 2001US-269308P.

XX (ELIT-) ELITRA PHARM INC.

XX Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Travick JD, Carr GJ;  
PI Yamamoto RT, Xu HH;  
XX WPI: 2001-611495/70.  
DR P-PSDB; AAU37006.  
XX  
PT New polynucleotides for the identification and development of  
XX antibiotics, comprise sequences of antisense nucleic acids -  
XX  
PS Claim 27; Seq ID No 8502; 511pp; English.

XX The invention relates to antisense inhibitors of genes essential to  
CC prokaryotic cellular proliferation, their use in identifying the  
CC genes, their use in the discovery of novel antibiotics, the essential  
CC genes themselves and the encoded proteins. The prokaryotes used are  
CC Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella  
CC pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The  
CC invention is also useful for the identification of potential new targets  
CC for antibiotic development. The antisense nucleic acids can also be used  
CC to identify proteins used in proliferation, to express these proteins,  
CC and to obtain antibodies capable of binding, to the expressed proteins.  
CC The proteins can be used to screen compounds in rational drug discovery  
CC programmes. The antisense nucleic acid sequence is also useful to screen  
CC for homologous nucleic acids which are required for cell proliferation in  
CC essential prokaryotic cellular proliferation protein.  
CC Note: The sequence data for this patent did not form part  
CC of the printed specification, but was obtained in electronic  
CC format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences.

XX Sequence 1311 BP; 451 A; 181 C; 277 G; 402 T; 0 other;

Query Match 99.2%; Score 383.8; DB 23; Length 1311;  
Best Local Similarity 99.5%; Pred. No. 1.4e-97;  
Matches 385; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GATCTTCTCTCTTACCAAAATGAGAACTGTCATCTAACAAGTCACCAAGACCTA 60  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
508 GATCTTCTCTCTTACCAAAATGAGAACTGTCATCTAACAAGTCACCAAGACCTA 449  
Qy 61 AACCATGTGACCTGATATCGGATACGGTTCCACCAATCCTTAATGAATAGATACATA 120  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
448 AACCATGTGACCTGATATCGGATACGGTTCCACCAATCCTTAATGAATAGATACATA 389  
Qy 121 CGTCTGACGATTCCTCATATCTACTTTGTAACCGCTTAATGACCGGTTTTTAG 180  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
388 CGTCTGACGATTCCTCATATCTACTTTGTAACCGCTTAATGACCGGTTTTTAG 329  
Qy 181 ATTTGTATAAATTTGAGCGCATTTTCATCGCTTTGTGTCATCTTACCGACCGTTAA 240  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
328 ATTTGTATAAATTTGAGCGCATTTTCATCGCTTTGTGTCATCTTACCGACCGTTAA 269  
Qy 241 CCATAAAATAAATTAACATCCGCTTCATCTATGGGATTTCTGCTGGCTCTAATTTGTG 300  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
268 CCATAAAATAAATTAACATCCGCTTCATCTATGGGATTTCTGCTGGCTCTAATTTGTG 209  
Qy 301 TTTGGAATGGTGATCACCACCAATTTCAATACCACTGTATCAATAATTTGAATCATGTG 360



|||||  
 208 TTTGGATGGTCATCACCATTTCATACACCGTGTATCATATATTTGAATCATGTG 149  
 361 TTACCACTTCACCTGAAGAATAATAC 387  
 148 TTAACCACTCACCTGAAGAATAATAC 122

RESULT 6  
 AAV74669/c  
 ID AAV74669 standard; DNA; 3621 BP.  
 XX AAV74669;  
 XX  
 XX  
 XX  
 XX 16-MAR-1999 (first entry)  
 DE Staphylococcus aureus contig SEQ ID #358.  
 XX  
 XX Computer readable medium; vaccine; S.aureus infection; immunodetection;  
 KW cellulitis; eyelid infection; food poisoning; osteomyelitis; therapy;  
 KW skin infection; surgical wound infection; scalded skin syndrome;  
 KW toxic shock syndrome; ds.  
 XX  
 XX Staphylococcus aureus.  
 OS  
 FH Key Location/Qualifiers  
 FT misc\_feature 481..540  
 FT /tag= a  
 FT /note= "these bases represent a line of missing text in  
 the sequence listing in the specification. They  
 are included to maintain the nucleotide numbering  
 given in the specification for this DNA sequence"  
 FT misc\_feature 2281..2340  
 FT /tag= b  
 FT /note= "these bases represent a line of missing text in  
 the sequence listing in the specification. They  
 are included to maintain the nucleotide numbering  
 given in the specification for this DNA sequence"  
 XX  
 XX EP786519-A2.  
 XX  
 XX 30-JUL-1997.  
 XX  
 XX 07-JAN-1997; 97EP-0100117.  
 XX  
 XX 05-JAN-1996; 96US-0009861.  
 XX  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 XX  
 XX Barash SC, Choi GH, Dillon PJ, Fannon MR, Kunsch CA;  
 PI Rosen CA;  
 XX  
 XX WPI; 1997-374922/35.  
 XX  
 XX Polynucleotide(s) and proteins derived from Staphylococcus aureus  
 PT stored on computer readable medium and used in the production of  
 PT anti-S.aureus vaccines  
 XX  
 XX Claim 1; Page 1241-1243; 3271pp; English.  
 XX  
 CC This sequence represents one of 5191 Staphylococcus aureus DNA sequences  
 CC of the invention. The DNA sequences are recorded on a computer readable  
 CC medium, preferably selected from a floppy or hard disk, random access  
 CC memory (RAM), read-only memory (ROM) or CD-ROM. Homology searches using  
 CC the S.aureus DNA sequences allows putative functions to be assigned so  
 CC that protein-encoding or regulatory regions of commercial, therapeutic or  
 CC industrial importance can be obtained. Specifically, sequences which are  
 CC likely to encode antigens have been identified and these polypeptides can  
 CC be used in a vaccine composition against S.aureus infection. The  
 CC polypeptides can also be used in a kit for the immunodetection of  
 CC S.aureus in a sample. S.aureus is implicated in numerous human diseases,  
 CC including cellulitis, eyelid infections, food poisoning, osteomyelitis,  
 CC skin and surgical wound infections, scalded skin syndrome, toxic shock

CC syndrome, etc. Organisms transformed with the DNA sequences can be used  
 CC for recombinant production of the polypeptides. The new DNA sequences  
 CC (and their fragments) are useful as primers or probes for isolating  
 CC homologues of any of the S.aureus DNA sequences contained on the  
 CC computer readable medium.

XX Sequence 3621 BP; 1279 A; 442 C; 692 G; 1085 T; 123 other;

Query Match 84.5%; Score 327; DB 18; Length 3621;  
 Best Local Similarity 84.5%; Pred. No. 1.6e-81;  
 Matches 327; Conservative 0; Mismatches 60; Indels 0; Gaps 0;

QY 1 GATCTTCTCTCTTCCACCAAAATGAGAAACAACTGCATCTAACAAGTCACCAAGACCTA 60  
 DB 2637 GATCTTCTCTCTTCCACCAAAATGAGAAACAACTGCATCTAACAAGTCACCAAGACCTA 2578  
 QY 61 AACCATGTGACCGTGTATCGGATACGGTTACCAAAATCCTTAATGAATAGAAATCATACA 120  
 DB 2577 AACCATGTGACCGTGTATCGGATACGGTTACCAAAATCCTTAATGAATAGAAATCATACA 2518  
 QY 121 CGTGTACCGATTTCATATATCTACTTCTTAAACCGCTTAATACACCGGTTTTTTAG 180  
 DB 2517 CGTGTACCGATTTCATATATCTACTTCTTAAACCGCTTAATACACCGGTTTTTTAG 2458  
 QY 181 ATTTGTATATAAAATTTGAGCCACCATTTTCATCCCTTTGTGTCATCTTTCACGACGTTAA 240  
 DB 2457 ATTTGTATATAAAATTTGAGCCACCATTTTCATCCCTTTGTGTCATCTTTCACGACGTTAA 2398  
 QY 241 CCATATAAAATTAATAACATCCGCTTCATCTATGCGCATTTCTGCTGGGCTCTAATTTGTG 300  
 DB 2397 CCATATAAAATTAATAACATCCGCTTCATCTATGCGCATTTCTGCTGGGCTCTAATTTNNN 2338  
 QY 301 TTTGGAATGGTGCATCACCACCAATTTCAATACCACCTGTATCAATATATTTGAATCATGTG 360  
 DB 2337 NNGTG 2278  
 QY 361 TTAACCATTCACCTGAAGAATAAATAC 387  
 DB 2277 TTAACCATTCACCTGAAGAATAAATAC 2251

## RESULT 7

AAS50706  
 ID AAS50706 standard; DNA; 372 BP.

XX AAS50706;

XX 13-FEB-2002 (first entry)

XX Staphylococcus aureus cellular proliferation inhibitory sequence #1930.

XX Antisense; ss; prokaryotic cellular proliferation;

XX antibiotic; antibacterial; drug design.

XX Staphylococcus aureus.

XX WO200170955-A2.

XX 27-SEP-2001.

XX 21-MAR-2001; 2001WO-US09180.

XX 21-MAR-2000; 2000US-191078P.

PR 23-MAY-2000; 2000US-205848P.

PR 26-MAY-2000; 2000US-207727P.

PR 23-OCT-2000; 2000US-24578P.

PR 27-NOV-2000; 2000US-253625P.

PR 22-DEC-2000; 2000US-257931P.

PR 16-FEB-2001; 2001US-269308P.

XX (ELIT-) ELITRA PHARM INC.

XX Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Travick JD, Carr GJ;

PI

PI Yamamoto RT, Xu HH;  
XX WPI: 2001-611495/70.  
XX  
XX New polynucleotides for the identification and development of  
XX antibiotics, comprise sequences of antisense nucleic acids -  
XX  
XX Claim 1: Seq ID No 3283; 511pp; English.  
XX  
XX The invention relates to antisense inhibitors of genes essential to  
XX prokaryotic cellular proliferation, their use in identifying the  
XX genes, their use in the discovery of novel antibiotics, the essential  
XX genes themselves and the encoded proteins. The prokaryotes used are  
XX *Escherichia coli*, *Staphylococcus aureus*, *Salmonella typhi*, *Klebsiella*  
XX *pneumoniae*, *Pseudomonas aeruginosa* and *Enterococcus faecalis*. The  
XX invention is also useful for the identification of potential new targets  
XX for antibiotic development. The antisense nucleic acids can also be used  
XX to identify proteins used in proliferation, to express these proteins,  
XX and to obtain antibodies capable of binding to the expressed proteins.  
XX The proteins can be used to screen compounds in rational drug discovery  
XX for homologous nucleic acids which are required for cell proliferation in  
XX a wide variety of organisms. The present sequence is an antisense  
XX oligonucleotide of the invention.  
XX Note: The sequence data for this patent did not form part  
XX of the printed specification, but was obtained in electronic  
XX format directly from Wipo at  
XX [ftp.wipo.int/pub/published\\_pct\\_sequences](http://ftp.wipo.int/pub/published_pct_sequences).  
XX  
SQ Sequence 372 BP; 113 A; 83 C; 51 G; 125 T; 0 other;  
  
Query Match 76.2%; Score 295; DB 23; Length 372;  
Best Local Similarity 100.0%; Pred. No. 7e-73;  
Matches 295; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 93 CCAATCTTAATGAATAGAAATCATACACGCTGTGACGATTTCCATATATCTACTTTG 152  
DB 1 CCAATCTTAATGAATAGAAATCATACACGCTGTGACGATTTCCATATATCTACTTTG 60  
  
QY 153 TTAACCGCTAATACGACGGTTTTTATGATTTGTATATAAATTTGAGGACCATTTTCATCG 212  
DB 61 TTAACCGCTAATACGACGGTTTTTATGATTTGTATATAAATTTGAGGACCATTTTCATCG 120  
  
QY 213 CTTTGTGTCATCTTCACGACGTTAACCATATAAATAATTAACATCCGCTTCTCATGTG 272  
DB 121 CTTTGTGTCATCTTCACGACGTTAACCATATAAATAATTAACATCCGCTTCTCATGTG 180  
  
QY 273 GCGATTTCTGCGCTCTAAATTTGTGTTGGATGGTGATCCCAATTTCAATACCA 332  
DB 181 GCGATTTCTGCGCTCTAAATTTGTGTTGGATGGTGATCCCAATTTCAATACCA 240  
  
QY 333 CCGTATCAATATATTGAATCATGTGTTAACCATTTCAACCATTTCAACCATTTCAATAC 387  
DB 241 CCGTATCAATATATTGAATCATGTGTTAACCATTTCAACCATTTCAATAC 295  
  
RESULT 8  
ABN90883/c  
ID ABN90883 standard; DNA; 1332 BP.  
XX  
XX ABN90883;  
XX  
XX 24-JUL-2002 (first entry)  
XX  
XX DE Staphylococcus epidermidis ORF nucleic acid sequence SEQ ID NO:346.  
XX  
XX KW Staphylococcus epidermidis; open reading frame; ORF; bacterial infection;  
XX antibacterial; gene therapy; gene; ds.  
XX  
XX OS Staphylococcus epidermidis.  
XX  
XX PN US6380370-B1.  
XX

PD 30-APR-2002.  
XX  
XX 13-AUG-1998; 98US-0134001.  
XX  
XX 14-AUG-1997; 97US-055779P.  
XX 08-NOV-1997; 97US-064964P.  
XX  
XX (GENO-) GENOME THERAPEUTICS CORP.  
XX  
XX Doucette-Stamm LA, Bush D;  
XX WPI: 2002-381255/41.  
XX P-PSDB; ABP38338.  
XX  
XX Novel isolated nucleic acid encoding a *Staphylococcus epidermidis* -  
XX polypeptide, useful for diagnosing and treating bacterial infections -  
XX  
XX Disclosure: SEQ ID 346; 267pp; English.  
XX  
XX ABN90538 to ABN93374 represent *Staphylococcus epidermidis* open reading  
XX frame (ORF) nucleic acid sequences which encode the amino acid sequences  
XX given in ABP35124 to ABP37960. The *S. epidermidis* sequences have  
XX antibacterial activity and can be used in gene therapy. The sequences  
XX can also be used in the diagnosis and treatment of bacterial infections,  
XX particularly *S. epidermidis* infections. The sequences can be used to  
XX screen for compounds able to interfere with the *S. epidermidis* life  
XX cycle or inhibit *S. epidermidis* infection.  
XX N.B. The sequence data for this patent did not form part of the printed  
XX specification, but was obtained in electronic format directly from the  
XX USPTO web site.  
XX  
SQ Sequence 1332 BP; 465 A; 190 C; 267 G; 410 T; 0 other;  
  
Query Match 67.8%; Score 262.2; DB 24; Length 1332;  
Best Local Similarity 79.8%; Pred. No. 1.6e-63;  
Matches 309; Conservative 0; Mismatches 78; Indels 0; Gaps 0;  
  
QY 1 GATCTTCTTCTCTTTCACCAAAATGAGAAACAACTGCATCTAACAGTCACCAAGACCTA 50  
DB 529 GATCTTCTTCTCTTTCATTAAGTTTTCACCAAACTGCATCTAGCAAAATCTCCAAGTCTA 470  
  
QY 61 AACCATGTGACCGCTCATATCGGATACGTTTCACCAAAATGCTTAATGAAGAAATCATACA 120  
DB 469 ATCCATGTGACCAAGAAATAGGATATGGATCTCCAAAGCTAAAGAAATGAATCATAGA 410  
  
QY 121 CGTCTGACGCAATTTCCATATATCTACTTTGTTAAACCGCTTAATACGACCGGTTTTTAG 180  
DB 409 TATCATTCAGCAATTTCAAGATTTCACTTTATTCACAGCTAATACACAGGTTTCTTAG 350  
  
QY 181 ATTTGTATAAAATTTGAGGACCAATTTTCATCGCTTTGTGTCAATGCTTCACGACGTTAA 240  
DB 349 ATTTATAAAGCAATTTGTGCGACCAATTTGCGTCACTTTGTGTAGTCTCTTCTTAACATTGA 290  
  
QY 241 CCATAAAATAAATACATCCGCTTCTCATCTATGGCGATTTCTGCGCTCGCTCTTAATTTGTG 300  
DB 289 CCATAAAATGATGACATCTGCTTCTTCAATTTCTGCTCTGCGACGATTTGTAG 230  
  
QY 301 TTTTGAATGTGTCATCCACCAATTTCAATACCACTGTATCAATTAATTAATTAATCATGTG 360  
DB 229 TTTGAAAGGAGGATCTCCAATTTCAATACCACTGTATCAATTAATTAATTAATCATG 170  
  
QY 361 TTAACCATTCACCTGAAGAAATTAATAC 387  
DB 169 TTAACCATTCGCGCAGATGAATAATAC 143  
  
RESULT 9  
AAH54708  
ID AAH54708 standard; DNA; 3269 BP.  
XX  
XX AAH54708;  
XX  
XX 03-SEP-2001 (first entry)  
XX

XX DE S. epidermidis genomic polynucleotide sequence SEQ ID NO:4072.  
 XX KW Staphylococcus epidermidis SRI strain; infection; diagnosis;  
 XX KW vaccination; endocarditis; ds.  
 XX OS Staphylococcus epidermidis.  
 XX PN WO200134809-A2.  
 XX PD 17-MAY-2001.  
 XX PF 09-NOV-2000; 2000WO-US30782.  
 XX PR 09-NOV-1999; 99US-0164258.  
 XX PA (GLAXO) GLAXO GROUP LTD.  
 XX PI Kimmberly WJ;  
 XX XX WPI; 2001-316495/33.  
 XX DR Nucleic acids encoding polypeptides from Staphylococcus epidermidis,  
 XX PT useful for vaccinating against infections, e.g. endocarditis -  
 XX PS Claim 8; Page 1757-1759; 2188pp; English.  
 XX CC AAH53970 represent nucleic acids (I) encoding polypeptides  
 CC (II), given in AAG81454 to AAG83120, from Staphylococcus epidermidis.  
 CC (I) and (II) can have antibacterial activity and therefore can be used  
 CC in vaccination. The nucleic acids (I) may be used to produce the  
 CC S. epidermidis polypeptides (II) via the production of vectors  
 CC containing them which are used to produce hosts cells which express the  
 CC polypeptides. The polypeptides (II) (and/or nucleic acids) may then be  
 CC used to vaccinate subjects and to raise antibodies against the bacteria.  
 CC The polypeptides may also be used to assay for other inhibitors of their  
 CC activity and therefore identify compounds that may be used for the  
 CC treatment of S. epidermidis infections, e.g. endocarditis. AAH53971 to  
 CC AAH55090 represent specifically claimed S. epidermidis genomic DNA  
 CC polynucleotide sequences from the present invention. AAH55091 to  
 CC AAH55098 represent oligonucleotide sequences and primers which are used  
 CC in the exemplification of the present invention.  
 CC N.B. The present invention specifically claims all the polynucleotide  
 CC sequences given in the sequence listing of the present specification.  
 CC however the sequence listing only goes up to SEQ ID NO.4454 so even  
 CC though sequences are given in the disclosure for SEQ ID NO:4465 to 4472,  
 CC no sequences are present for SEQ ID NO:4455 to 4464.  
 XX SQ Sequence 3269 BP; 986 A; 516 C; 451 G; 1216 T; 0 other;

Query Match 67.8%; Score 262.2; DB 22; Length 3269;  
 Best Local Similarity 79.8%; Pred. No. 2.1e-63;  
 Matches 309; Conservative 0; Mismatches 78; Indels 0; Gaps 0;

OY 1 GATCTTCTTCTTCCACCAAAATGAGAAACACTGCTTAAACAGTCACCAAGACCTA 60  
 DB 2297 GATCTTCTGATCTTTTATTAAAGTTTTCACCAACTGCTATGCAATCTCCAGTCCTA 2356  
 OY 61 APCCATGTCACCTGATATCGGATACGGTTCCACCAATCTCTATGATAGATACATCA 120  
 DB 2357 ATCATGTGACCAAGAAATAGATATGATCTCCAAAGCTTAAGATAGATATCATGA 2416  
 OY 121 CGTCTGACGANTTCCATATATATCTATCTTTGTTAAACGGCTATACGACGGTTTTT 180  
 DB 2417 TATCATATGCGATTTTCAGATATATCAACTTTTATTCACAGCTATATACACAGGTTCT 2476  
 OY 181 ATTGTATATAAATTTGAGGACCATTTTCATGCTTTGTGTCATCTTCACGACCTTAA 240  
 DB 2477 ATTATAAAGCATTTTGTGCGACCATTTGCTACCTTTGTTGAAGTCTTCTCTAACAT 2536  
 OY 241 CCATAAAATATAACATCCGCTTCATCTATGGGATTTCTGCTGCGCTCTATTTG 300  
 DB 2537 CCATAAAATGATGACATCTGCTTCTTCAATGCTATTTCTGCTGCGACGATTTGAG 2596

OY 301 TTGGAATGGTGTCATCCACCAATTTCAATACCACTGTATCAATAATATTTGAATCATGTG 360  
 DB 2597 TTGGAAGGAGCATCTCCCAATTTCAATACCACTGTATCAATGATGTTAAATTCATGAG 2656  
 OY 361 TTACCACTTCCACCTGAGATTAATCAATCAATCAATCAATCAATCAATCAATCAAT 387  
 DB 2657 TTACCACTTCCACCTGAGATTAATCAATCAATCAATCAATCAATCAATCAATCAAT 2683

RESULT 10  
 AAS50205  
 ID AAS50205 standard; DNA: 298 BP.  
 XX AAS50205;  
 AC AAS50205;  
 DT 13-FEB-2002 (first entry)  
 XX Staphylococcus aureus cellular proliferation inhibitory sequence #1429.  
 DE Staphylococcus aureus cellular proliferation inhibitory sequence #1429.  
 XX Antisense: ss: prokaryotic cellular proliferation;  
 KW antibiotic; antibacterial; drug design.  
 XX Staphylococcus aureus.  
 OS Staphylococcus aureus.  
 XX WO200170955-A2.  
 PN 27-SEP-2001.  
 PD 21-MAR-2001; 2001WO-US09180.  
 PF 21-MAR-2000; 2000US-191078P.  
 XX 23-MAY-2000; 2000US-206848P.  
 PR 26-MAY-2000; 2000US-207727P.  
 PR 23-OCT-2000; 2000US-242578P.  
 PR 27-NOV-2000; 2000US-253823P.  
 PR 22-DEC-2000; 2000US-259331P.  
 PR 16-FEB-2001; 2001US-269308P.  
 XX (ELIT-) ELITRA PHARM INC.  
 XX Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;  
 PI Yamamoto RT, Xu HH;  
 DR WPI; 2001-611495/70.  
 XX New polynucleotides for the identification and development of  
 PT antibiotics, comprise sequences of antisense nucleic acids -

Claim 1: Seq ID No 2782: 51pp; English.

The invention relates to antisense inhibitors of genes essential to prokaryotic cellular proliferation, their use in identifying the genes, their use in the discovery of novel antibiotics, the essential genes themselves and the encoded proteins. The prokaryotes used are Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The invention is also useful for the identification of potential new targets for antibiotic development. The antisense nucleic acids can also be used to identify proteins used in proliferation, to express these proteins, and to obtain antibodies capable of binding to the expressed proteins. The proteins can be used to screen compounds in rational drug discovery programmes. The antisense nucleic acid sequence is also useful to screen for homologous nucleic acids which are required for cell proliferation in a wide variety of organisms. The present sequence is an antisense oligonucleotide of the invention.  
 CC Note: The sequence data for this patent did not form part  
 CC of the printed specification, but was obtained in electronic  
 CC format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences.

Sequence 298 BP; 91 A; 69 C; 43 G; 95 T; 0 other;

CC programmes. The antisense nucleic acid sequence is also useful to screen  
CC for homologous nucleic acids which are required for cell proliferation in  
CC a wide variety of organisms. The present sequence is an antisense  
CC oligonucleotide of the invention.  
CC Note: The sequence data for this patent did not form part  
CC of the printed specification, but was obtained in electronic  
CC format directly from WIPO at  
CC [ftp.wipo.int/pub/published/pct-sequences](http://wipo.int/pub/published/pct-sequences).  
CC

DB 125 AACCAATGACCCCTGATCGGATACGGTTCACCAANTCCTAATGATGAANTCATACA 184

QY 121 CGTGTGACGCAATTCGCAATATATCTACTCTTTGTGTTAAACCGCTAATACGACCGGTTTTTTAG 180

DB 185 COTGTGTACGGCAATTCGCAATATATCTACTCTTTGTGTTAAACCGCTAATACGACCGGTTTTTTAG 244

QY 181 ATTTGTATAAAAATTGAGCGACCACTTTCATCGCTTTGTGTCATCTCTTCACGCA 234

DB 245 ATTTGTATAAAAATTGAGCGACCACTTTCATCGCTTTGTGTCATCTCTTCACGCA 298

## RESULT 12

ABQ67194/C  
ID ABQ67194 standard; DNA; 319630 BP.

AC ABQ67194;

DT 29-AUG-2002 (first entry)

DE *Listeria innocua* contig DNA sequence #7.

KW Antibacterial; Listeria; food contamination; mutational analysis;  
infection; de

XX  
OS  
Lister's Innocua

XX  
PN WQ200228891-A2.

XX PD 11-APR-2002.

XX  
PF 04-OCT-2001; 2001WO-FR03061.

XX PR 04-OCT-2000; 2000FR-0012597.

XX  
PA ( INSP ) INST PASTEUR.

XX  
XX  
(CNFS) CENSUS NAT FETH 2011.

XX  
Ft RUSSEL F, GILBERT F,  
XX

XX  
XX

PT treatment and prevention of infection, also related polypeptides,

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	52
--	---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	----

[illegible]

CC (ABQ67188-ABQ71212) from *Listeria* sp. The sequences are useful as probes and primers for identification and/or detection of *Listeria* ( $\alpha$  and  $\beta$ ).

CC contaminants in foods, or mutational analysis) and for analysis of  
CC proteins encoded by the nucleic acid sequences can be  
CC done overexpression





```
|||||
489 AAAATGTTGGCTGACCGGTCAGCGAGATCGCGAGACCAAGCCCATGGTCCATGAAT 430
QY CGGATACGGTTCCACCAATCCTAATGATAGATATACACGCTCTGTACGGATTTCCAT 139
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
429 CGGGAACGGCTGCCAAAGCGGAGGCATAAAATCGTAATGTTGCTCTCATTTTCAGG 370
QY 140 ATATCTACTTTGTTAACCGCTAATACGACGGTTTTTTTAGATTTGTATAAAATTTGAGC 199
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
369 ATATCCACTTTTAAACCGGCAGACGACGGGTTTTTTGTACGGTATAAAATTTTGGC 310
QY 200 GACCATTTTCATCGCTTTGTGTCATCCTTCACGCACGTTAACCCATAAAATAATAACATC 259
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
309 CACTTCTTCATCAGCGGCTGTGACGCCCTTCGCGGCCGTTCGTCAATGAAATAATCACATC 250
QY 260 CGCTTCATCTATGGCGATTTCTGCTGCGCTCTAATTTGTTTGCATGTTGCTATCACC 319
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
249 TGCTTCTTCCATGGCGATCTCGGCTGATGGCGAATCTGCGCCAAAACGGCTCATCGCC 190
QY 320 AATTCAATACCGCTGTATCAATAATATTGAATCATGTGTTAACCATTCACCTGAAGA 379
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
189 GACTTCGATTCGCGCTGTATCAATCAGGTTGAAGTCGTGATTCAGCCACTCGGCAGAGCT 130
QY 380 ATAAATAC 387
Db ||| |||
129 GTATATCC 122
```

Search completed: September 12, 2003, 17:32:09  
Job time : 138.915 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 12, 2003, 17:17:09 : Search time 1580.02 Seconds  
(without alignments)  
10020.134 Million cell updates/sec

Title: US-09-815-242-1463  
Perfect score: 387  
Sequence: 1 gatcttctctcttcacca.....ttcacctgaagaataaac 387

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 2888711 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

#### Database :

##### GenEmbl.\*

1: gb.ba.\*  
2: gb.hig.\*  
3: gb.in.\*  
4: gb.on.\*  
5: gb.ov.\*  
6: gb.pat.\*  
7: gb.ph.\*  
8: gb.pl.\*  
9: gb.pr.\*  
10: gb.ro.\*  
11: gb.sts.\*  
12: gb.sy.\*  
13: gb.un.\*  
14: gb.vi.\*  
15: em.ba.\*  
16: em.fun.\*  
17: em.hum.\*  
18: em.in.\*  
19: em.mu.\*  
20: em.ov.\*  
21: em.or.\*  
22: em.pat.\*  
23: em.ph.\*  
24: em.pl.\*  
25: em.ro.\*  
26: em.sts.\*  
27: em.un.\*  
28: em.vi.\*  
29: em.htg.hum.\*  
30: em.htg.inv.\*  
31: em.htg.other.\*  
32: em.htg.mus.\*  
33: em.htg.pln.\*  
34: em.htg.rod.\*  
35: em.htg.vrt.\*  
36: em.htg.man.\*  
37: em.htg.vrt.\*  
38: em.sy.\*  
39: em.htgo.hum.\*  
40: em.htgo.mus.\*  
41: em.htgo.other.\*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

#### SUMMARIES

Result NO.	Score	Match	Length	DB	ID	Description
C 1	387	100.0	1308	6	AX622668	Sequence
C 2	387	100.0	301550	1	AP003134	Staphyloc
C 3	387	100.0	333750	1	AP004827	Staphyloc
C 4	387	100.0	345900	1	AP003362	Staphyloc
C 5	262.2	67.8	3269	1	AF270032	Staphyloc
C 6	262.2	67.8	3269	1	AF270032	Sequence
C 7	262.2	67.8	300892	1	AE016747	Staphyloc
C 8	210.6	54.4	290117	1	AE017028	Bacillus
C 9	209	54.0	304680	1	AE017002	Bacillus
C 10	205.8	53.2	313450	1	AL596170	Listeria
C 11	205.8	53.2	319630	6	AX413016	Sequence
C 12	205.8	53.2	347050	1	AL591981	Listeria
C 13	205.8	53.2	349980	6	AX417046	Sequence
C 14	205.8	53.2	349980	6	AX417046	Sequence
C 15	198.4	51.3	24887	1	BACSER4	Sequence
C 16	198.4	51.3	213680	1	BSUR0012	Bacillus su
C 17	191.4	49.5	302173	1	AE016951	Enterococ
C 18	188.2	48.6	300050	1	AP004599	Oceanococ
C 19	185	47.8	300550	1	AP001512	Bacillus
C 20	182.4	47.1	302050	1	AL935257	Lactobaci
C 21	174.4	45.1	1311	6	AX433884	Sequence
C 22	162.6	42.0	11071	1	AE006309	Lactococc
C 23	162.6	42.0	12434	1	AE006498	Streptoco
C 24	162	41.9	1311	6	AX607165	Sequence
C 25	162	41.9	44145	6	AX602195	Sequence
C 26	162	41.9	174050	1	SAG766852	Streptoco
C 27	160.4	41.4	20601	1	AE014265	Streptoco
C 28	159.4	41.2	52276	1	AE014141	Streptoco
C 29	159.4	41.2	323825	1	AP005146	Streptoco
C 30	157.8	40.8	12370	1	AE009978	Streptoco
C 31	153	39.5	12540	6	AE008523	Streptoco
C 32	151.4	39.1	1308	6	AX570314	Sequence
C 33	151.4	39.1	5066	6	BD03759	Polynucle
C 34	151.4	39.1	5066	6	BD03759	Sequence
C 35	151.4	39.1	10310	1	AE007464	Streptoco
C 36	151.4	39.1	151947	2	SPNEU1902	Streptoco
C 37	151.4	39.1	349580	6	AX571764	Sequence
C 38	151.4	39.1	349580	6	AX571765	Sequence
C 39	149.8	38.7	13860	1	AE015016	Streptoco
C 40	148.2	38.3	3737	1	AB016077	Streptoco
C 41	139.4	36.0	301278	1	AE015939	Clostridi
C 42	125.2	32.4	296750	1	AP003191	Clostridi
C 43	117	30.2	10861	1	AE007680	Clostridi
C 44	109.2	28.2	3557	1	AY094626	Lactobaci
C 45	101	26.1	960	6	AX144037	Sequence

#### ALIGNMENTS

RESULT 1  
AX622668/c  
LOCUS AX622668 1308 bp DNA linear PAT 20-FEB-2003  
DEFINITION Sequence 5631 from Patent WO02094868.  
ACCESSION AX622668  
VERSION AX622668.1 GI:28450653  
KEYWORDS Staphylococcus aureus  
SOURCE Staphylococcus aureus  
ORGANISM Bacteria; Firmicutes; Bacillales; Staphylococcus.  
REFERENCE 1  
AUTHORS Haganani, V.C., Mora, M.C. and Scarselli, M.C.  
TITLE Staphylococcus aureus proteins and nucleic acids  
JOURNAL Patent: WO 02094868-A 5631 28-NOV-2002;  
Chiron Spa (IT)



```
FEATURES
  source          Location/Qualifiers
1. 1308
   /organism="Staphylococcus aureus"
   /mol_type="genomic DNA"
   /db_xref="taxon:1280"
BASE COUNT      450 a 184 c 278 g 396 t
ORIGIN
Query Match      100.0%; Score 387; DB 6; Length 1308;
Best Local Similarity 100.0%; Pred. NO. 2e-77;
Matches 387; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GATCTCTTCTCTTACCAAAATGAGAAACAACTGCATCTAACAAGTCACCAAGACCTA 60
   |||
Db 508 GATCTCTTCTCTTACCAAAATGAGAAACAACTGCATCTAACAAGTCACCAAGACCTA 449
QY 61 AACCATGTGACCTGATATCGGATACGGTTCCACCAATCTTAATGAATGAATCATACA 120
   |||
Db 448 AACCATGTGACCTGATATCGGATACGGTTCCACCAATCTTAATGAATGAATCATACA 389
QY 121 CGCTGTAGCGATTTCCATATATCTACTTTGTTAAACCGCTAATACGACCGTTTTAG 180
   |||
Db 388 CGCTGTAGCGATTTCCATATATCTACTTTGTTAAACCGCTAATACGACCGTTTTAG 329
QY 181 ATTGTATAAAATTTGACGACCAATTCATCGCTTTGTGTCATCTTCCACGACGTAA 240
   |||
Db 328 ATTGTATAAAATTTGACGACCAATTCATCGCTTTGTGTCATCTTCCACGACGTAA 269
QY 241 CCATATAAATAATACATCCGCTTCATCTATGCGATTTCTGCGCTCGCTCTAATTTGTG 300
   |||
Db 268 CCATATAAATAATACATCCGCTTCATCTATGCGATTTCTGCGCTCGCTCTAATTTGTG 209
QY 301 TTGGAATGGTCATCACCAATTTCAATACACCGTGTATCAATATTAATGAATCATGTG 360
   |||
Db 208 TTGGAATGGTCATCACCAATTTCAATACACCGTGTATCAATATTAATGAATCATGTG 149
QY 361 TTAACCATTCACCTGAAGAATAATAC 387
   |||
Db 148 TTAACCATTCACCTGAAGAATAATAC 122

RESULT 2
AP003134
LOCUS
DEFINITION
Staphylococcus aureus subsp. aureus N315 genomic DNA, complete
genome, section 5/10.
AP003134 BA000018
ACCESSION
AP003134.2 GI:14349226
KEYWORDS
Staphylococcus aureus subsp. aureus N315
SOURCE
Staphylococcus aureus subsp. aureus N315
ORGANISM
Bacteria; Firmicutes; Bacillales; Staphylococcus.
REFERENCE
1 Kuroda.M., Ohta.T., Uchiyama.I., Baba.T., Yuzawa.H., Kobayashi.I.,
  Cui.L., Oguchi.A., Aoki.K., Nagai.Y., Lian.J., Ito.T., Kanamori.M.,
  Matsumaru.H., Maruyama.A., Murakami.H., Hosoyama.A.,
  Mizutani-U.I.Y., Takahashi.N.K., Sawano.T., Inoue.R., Kaito.C.,
  Sekimizu.K., Hirakawa.H., Kuhara.S., Goto.S., Yabuzaki.J.,
  Kanehisa.M., Yamashita.A., Oshima.K., Furuya.K., Yoshino.C.,
  Shiba.T., Hattori.M., Ogasawara.N., Hayashi.H. and Hiramatsu.K.
  Whole genome sequencing of methicillin-resistant Staphylococcus
  aureus
Lancet 357 (9264), 1225-1240 (2001)
JOURNAL
Lancet 357 (9264), 1225-1240 (2001)
MEDLINE
21311952
PUBMED
11418146
REFERENCE
2 (bases 1 to 301550)
Director-General, Biotechnology Center, Aoki.K., Oguchi.A.,
Hosoyama.A., Nagai.Y., Kuroda.M., Hiramatsu.K. and Kikuchi.H.
Direct Submission
Submitted (30-JAN-2001) Director-General, Biotechnology Center,
National Institute of Technology and Evaluation, Biotechnology
Center, 2Chome 49-10 Nishihara, Shibuya-ku, Tokyo 151-0065, Japan
(E-mail:bio@nite.go.jp, URL:http://www.bio.nite.go.jp/.
```

```

Tel:81-3-3481-1933, Fax:81-3-3481-8424)
On Jun 12, 2001 this sequence version replaced gi:13701258.
Location/Qualifiers
1. 301550
   /organism="Staphylococcus aureus subsp. aureus N315"
   /mol_type="genomic DNA"
   /strain="N315"
   /sub_species="aureus N315"
   /db_xref="taxon:158879"
   /gene="SA1293"
   /complement(249..947)
   /gene="SA1293"
   /complement(249..947)
   /note="ORFID:SA1293"
   /codon_start=1
   /transl_table=11
   /product="conserved hypothetical protein"
   /protein_id="BAB42553.1"
   /db_xref="GI:13701259"
   /translation="MSISFTMIYIVLWPLHQAQHKVSNYKYSQVASTSGKTGR
EVALEIHANGIYDVVYVKGESFLIDHDPKKVVSLSPPANDRPSVAGTAIAAHEVG
HAIQDHGYNFRLFRALPVRNUGSSLSHIIMIGIILITAGSATSSTALWAGLML
SLAVLSIVLPVVEFDASSRANKQITALNIVNKEYKHARKVLSAAAATVVAATAVAY
AELVRIILIARSSD"
   /complement(1001..1588)
   /gene="SA1294"
   /complement(1001..1588)
   /gene="SA1294"
   /note="ORFID:SA1294"
   /codon_start=1
   /transl_table=11
   /product="conserved hypothetical protein"
   /protein_id="BAB42554.1"
   /db_xref="GI:13701260"
   /translation="MTINFTPOYTLQORSWMLMLICHLQIMYGYIYWGDSHTPW
HFKIFPDSPTAILLVLSISLLQKNSIEALAFVTLKYGKINAVIYNHILFIEQ
GDITVNGLVLPFSRISMAVGAIIFFIFPKRSPIGISVANIVFLNDITDFHLOPPIY
DFTTHVQIGVLSCCSVFGLLIITLNLKLKCK"
   /complement(1578..2153)
   /gene="SA1295"
   /complement(1578..2153)
   /gene="SA1295"
   /note="ORFID:SA1295"
   /codon_start=1
   /transl_table=11
   /product="conserved hypothetical protein"
   /protein_id="BAB42555.1"
   /db_xref="GI:13701261"
   /translation="MSETNLQIKESFIEYLLFOYBFKSRIAVWVLYIKVNEAKLMI
HFVDTKINHETLEIAEVGSHASATQFKNKIKLWNTNEIFDYIANHNCAPDIOIHPA
NYSRERLDDLIYVAQLTSPSPSYQIYLDLNSMAIDRHKHALLIDYLLHNDLSLQNN
EKQPIQTLTLLKLVNHNHOFEDLADD"
   /complement(2167..3411)
   /gene="SA1296"
   /complement(2167..3411)
   /gene="SA1296"
   /note="ORFID:SA1296"
   /codon_start=1
   /transl_table=11
   /product="conserved hypothetical protein"
   /protein_id="BAB42556.1"
   /db_xref="GI:13701262"
   /translation="MEDIVKLIIDINLQKLENSRVNEATTTDNDALFILTGLYN
EGLMROGLEVFRVLYHKYDSESLIYFIEGLMSNOTDEALEVLSYVSPSKLMLE
ADLYQOIKMVEAIDKLEALEPNDRPIIHFAEMLYXCOYLATSEKTVLETC
EYQVNGYNLESFADSCSGNYSQDAIKYIDENEDMTSEDIKKAKISDKNDITGC
AIKMTLLSKDPDYIGGLYIQSLUYENENKTPDAIETRGEGRLRSQFYRELMTTGC
LEIHDGANGVLLQALEVDNATQEPULLISDPIIRNEEDYIAISULTYVDEEDLD
PTFWHLAFAYGGEERKDEQAHPFLAYPTMTKNTIDFMSDYIFYLIIGIKGEQAIFIL
NQLLEPSPNENHDELSLQS"
   /complement(3418..4716)
   /gene="aroA"
   /complement(3418..4716)
   /complement(3418..4716)
```



Sat Sep 13 12:47:59 2003

TITLE	Genome and virulence determinants of high virulence	
	community-acquired MRSA	
JOURNAL	Lancet 359 (9320), 1819-1827 (2002)	
MEDLINE	22040717	
PUBMED	12044378	
REFERENCE	2 (bases 1 to 333750)	
AUTHORS	Director-General, Biotechnology Center, Aoki, K., Oguchi, A., Nagai, Y., Asano, K., Iwama, N., Baba, T., Kuroda, M., Hiramatsu, K. and Kikuchi, H.	
TITLE	Direct Submission	
	National Institute of Technology and Evaluation, Biotechnology Center, 2-chome 49-10 Nishihara, Shibuya-ku, Tokyo 151-0066, Japan (E-mail: bioelite.go.jp, URL: http://www.bio.nite.go.jp/)	
JOURNAL	Tel: 81-3-3481-1933 Fax: 81-3-3481-8424)	
FEATURES	Location/Qualifiers	
	1..333750	
source	/organism="Staphylococcus aureus subsp. aureus MW2"	
	/mol_type="genomic DNA"	
gene	/strain="MW2"	
	/db_xref="taxon:196620"	
CDS	complement(278..619)	
	/gene="MW1341"	
gene	complement(278..619)	
	/gene="MW1341"	
CDS	/note="ORFID:MW1341"	
	/codon_start=1	
gene	/transl_table=11	
	/product="hypothetical protein"	
CDS	/protein_id="BAB95206.1"	
	/db_xref="GI:21204510"	
gene	/translation="MTNITREYFDNLEQEDIVFAKNKLGSEAKPYLDEYHSLIIOY FKQNDIGNIDFDKNGYPVPMFNERIDYMIERKHYFMGTRQMKTFTELINMNA SYQRLANKQV"	
	complement(624..1283)	
CDS	/gene="nth"	
	complement(624..1283)	
gene	/gene="nth"	
	/note="ORFID:MW1342"	
CDS	/codon_start=1	
	/transl_table=11	
gene	/product="endonuclease-like protein"	
	/protein_id="BAB95207.1"	
CDS	/db_xref="GI:21204511"	
	/translation="MVKKKALEMDIVANPPDACELKNDHPFELTAVLLSAQCT QVLNRYTTEPKYKPEYLAQSDPELMDIRSLGLVHKAKNKKLQSLIQDN GEIPTHLESLACVGRKANYMVADEPRLSLAVDTVERYSKGLINRKNQVQ VEDRLCSVIPDRNRSHOIFDFGRHCLARRAKDCICPLEDCREGQKRYKASLKE A"	
gene	complement(1273..1959)	
	/gene="MW1343"	
CDS	complement(1273..1959)	
	/gene="MW1343"	
gene	/note="ORFID:MW1343"	
	hypothetical protein, similar to chromosome replication initiation protein dnaD	
CDS	/codon_start=1	
	/transl_table=11	
gene	/protein_id="BAB95208.1"	
	/db_xref="GI:21204512"	
CDS	/translation="MDKQLKARVYVIRRELLDHYSLDGLDQDLVLLKLIYASETS NKPSIELQKSTMPDRDITHVIONLQRELLQVQKDEGRFTYMNLDPFELAL SHLQKQMETKEQNSKEFKQLFVLEDTFAPLSPYEIETLMQWIDVDRHDSAIQ AALDANSLKLSKYMDRILLNKKNNVATIDDSRKIREKFNKPMHTVKTVPKFD WINGENLQK"	
	complement(2287..3579)	
gene	/gene="asnS"	
	complement(2287..3579)	
CDS	/gene="asnS"	
	/note="ORFID:MW1344"	
gene	/codon_start=1	
	/transl_table=11	
CDS	/product="asparaginyl-tRNA synthetase"	
gene	/protein_id="BAB95209.1"	
	/db_xref="GI:21204513"	
CDS	/translation="MKTIKAKOHLNODVTIGAWLTKNSCKIAFLQLRDGTGPMQ GYVYSEVDEEVFKLAKSITQESSLYTCTITEDNRSDLGYENQVKSIVISEADHP ITPNNGTEFLMDHRHLWRSKQYHAKINNEVIRATYEFENKDGFTIVDPPIITAS APGTSSELFTHYFOODAPLQSGOLYLEAAMAHAGVYFSFGTFRAEKSKTRHLLIE FMWIEGEMFLTHAESLEIQEYVTHVYKSVLENCKLEKILKILDETSKLEKATVPPR ISYDDAIEFLKSEGDDIEMGDFCATHAIANHOLPVTITNPTKIKPFTMQPNP ENETVLCADLIAPEGYGEIIGGSRVDDLELLEQRYVKEHGLDEEAYSYLDRRYGS VPCHGFLGLERTVAMISGVENHRETAFFPRLNRLYP"	
	complement(3901..6594)	
gene	/gene="ding"	
	complement(3901..6594)	
CDS	/gene="ding"	
	/note="ORFID:MW1345"	
gene	/codon_start=1	
	/transl_table=11	
CDS	/product="probable ATP-dependent DNA helicase ding"	
	/protein_id="BAB95210.1"	
gene	/db_xref="GI:21204514"	
	/translation="MGMATYAVDLETTGNOLDFFDDIIQIGITFVRNNQIIDYHSNI RTNLEIPPEFQALTSTENHMQQAFNQVAOEYDKIKOCIFYAHNVDFDLAFIKKA FKQCNIOYRPKKVIDTLEIFKIAFTDKSYQLSSELAHAHITLANAHRADEDAATKAK LMILAEKEKPLDITKOLYLSKQLYDIDYFFEMVROYDAKPLDKSYKEFDIIL YRKQVDFKPTTNGSLSKYKAVDQGLTYRPOQLYLAETILDQLMHSEKAMIEA SLGSGKSLAYLAALNHYETGKHYMISTNKLQSQLEKDPAPKNEALNFKNALL IKSKSDVISLGLISQILKDDTSNVEVNIKMLLITWITPSGDIQELNKGQKHYF DQKITYVPARHGVHYNFKRANQIQIIGITNHAHLIHSQVENSIOQLFDDCIVDEA HRLPDVALNOVTNELSYADIKYOLGIGLGNENKLLAKAQLEKQRIKDLQIAPIDI FGLKASMEITHELNEOLFSTIETIINDSDVDYDTHRFHNVFTFTKDIKLSQKSTIR KLNKTEIFNGISHTKYSLRKLQLYLKDQFNIEQSLKAGHTSFISIKNLSQKSTIR LYKQVAVDVLTKVLEKFKSLIFISCTLKNSHFAFKQFNKQVHNTFVMTSL QSAKNTSETPSDVASYQKNDENVASIVSYIETVITSSKLVLTSTYKMHMVQ DMNLEPSEDIYVQQQONAYKIQQNFNFKAILLGTSTFEKGFQANGIKQVM IAKLPFMKNKAKYMLDSEFTSTKEYLYLDDAVTRRQGLGLRLINSENDRGIIISFD DRLINSYKNFFETLENIRKQKGDIOQFGKLLRQIQKRAK"	
	complement(6618..7589)	
gene	/gene="MW1346"	
	complement(6618..7589)	
CDS	/gene="MW1346"	
	/note="ORFID:MW1346"	
gene	/codon_start=1	
	/transl_table=11	
CDS	/product="truncated hypothetical protein"	
	/protein_id="BAB95211.1"	
gene	/db_xref="GI:21204515"	
	/translation="MSKYSQDVLLLYKKNKPNYISGOSIAESLNSRTAVKKVIDOLK LEGCKIDSVNKHGHLQLQPLDIWYOGIIDQYTKSSALDFSEYVDSIDSTOLAAKSL VGNOSSEFLLSDQTKGRGRFNRHSSSKGGLGGLMWSVLRNPAFMSIKFNLFIALG IRDAIQHFSODEYKVKHPNDIYIDNKVCGGLTEWANNQGLEAICGIGINTQOLE NFESIRHRAISVQLHDKNKLDRYQFELERLQLEKSNQFLPLPESEIEEYIAASN IWNRTLLFTENDQKFGQAIDLDYDGTGLIVRDEAGESHRLISADIDF"	
	complement(7576..8778)	
gene	/gene="MW1347"	
	complement(7576..8778)	
CDS	/gene="MW1347"	
	/note="ORFID:MW1347"	
gene	hypothetical protein, similar to poly(A) polymerase"	
	/codon_start=1	
CDS	/transl_table=11	
	/protein_id="BAB95212.1"	
gene	/db_xref="GI:21204516"	
	/translation="MKSIFEQARPLEDIOINGFEAYVCGSVRDYVYKGRNTHDIDI TSATPDEIESISHTPIPVKKEGTLINVFNOENTEVITFRAEEDYVDHARPQGYTFY RDLVEDQRRDFTMNAIATKDKYDFDQGDINNRIITVIGIEREQDQALARI RCLRFQSLQSDIATATTFEAMRIQADIKFLSIEIRVIELTKLRGINKVSKNHLKQ LKAFNHPYFELDMQINVTAEIDLELLIAIVSVKFDINSKPLSKRQKRLNQ YIQNNALPSIITKEQLKHPYVDYDTHLKNYMAADVIVKANDIOGHEPLIVLQDID ETLHRLPMHNRKDMVNGVGVMAHLNKNKSGPWLKDVLRQIAIIVTKGVSNSETEILK WVDNHNKI"	
	complement(8783..9925)	
gene	/gene="MW1348"	
	complement(8783..9925)	



```
/translation="MISDENYLSGAHEKVLKRLVDTNLVQASGCGDQFTQAIEKI
KOTIDCPNATINFLVGGTQNOVYINSMLESYEGVISADTGHVAVHEGGAISGHV
ITIPCKEVSADVETMETFSKDFKDKHVPFGMYISHPTETGLYSKSEBELC
KVCYQIPLFMDGARGLGMSQSDMTIKDAKYCDVFIIGGTIGALCGEAIIVFT
KNEKQETTRIKHARGALLKRLTGIOLEFDTNLYENISRHAEMANKMKDGFKN
KGYRLVFSPTNQOFPILLSNEKIAELQKVKFAVWEKYDDQHRVVRFAATSWATTEENL
NKLEELI"
gene      3020..3217
CDS       /gene="SAV1316"
          3020..3217
          /gene="SAV1316"
          /codon_start=1
          /transl_table=11
          /product="hypothetical protein"
          /protein_id="BAB57481.1"
          /db_xref="GI:14247097"
/translation="MEQIKLTFTAETLELEKKNINAFLSSEATNKLNVNTIKIEI
ERTFPNESEFNAILTSVNK"
gene      3238..4755
CDS       /gene="SAV1317"
          3238..4755
          /gene="SAV1317"
          /codon_start=1
          /transl_table=11
          /product="cardiolipin synthetase homolog"
          /protein_id="BAB57479.1"
          /db_xref="GI:14247088"
/translation="MEFVFPEFGEKTHRYTFSNOLGTLFTIILAIGFIINLVAFIII
FLERNRTASSWAMLFVLPLIGFIYLFPGTVSARKLNKNGVLTDFDGLLK
QQESEDKNYGTDNKQVQKHDLVSMLLQDQGLFTEKNKVDHFIDGNDLYDVLKD
IKNAKEYIHLEYTFALDGLKRLHLEELKQGLVEYKILYDDVSGKNYKMANFDHF
KSLGGEVFAFFASKPLPLNFRNNRNHRKIIVIDGOLGVGGFNIGDEYLGKLGKGY
RDTLHQQDAVDALQDLREFLDNMSQAHRPQFEDVRYFPKKNGLPNSGIIQASGP
ASDHQIETGYTKIMHSAKSVYLOSIFYIPDSYINAIKAAKSGVDVHLMIPCKPD
HPLVWATFSNADLSGKVIYTYENGFIHSMKCLIDDEIVSGTAMMDRFSFELNF
EVNAFYVDNLAKDLRAVAYEHDITKSKOLTRESYANRPLSVKFKESLAKLVSPIL"
gene      4939..5436
CDS       /gene="SAV1318"
          4939..5436
          /gene="SAV1318"
          /note="ATP-binding protein"
          /codon_start=1
          /transl_table=11
          /product="ABC transporter homolog"
          /protein_id="BAB57480.1"
          /db_xref="GI:14247089"
/translation="MIQISNKNKPNKRCVLKNISFDIEQKQKIALIGKNGAKSTLI
DLIGNVANSGEIFDKKLQASNNKSFIMFKTFFDQLKVIENILYQSYFENPLPL
BEIETLKFDSSQLNQFVANKLGGQQRLDVLVSLIGQPOLILLIDPTSMOIEIREY
FWSII"
gene      5461..5838
CDS       /gene="SAV1319"
          5461..5838
          /gene="SAV1319"
          /note="ATP-binding protein"
          /codon_start=1
          /transl_table=11
          /product="ABC transporter homolog"
          /protein_id="BAB57481.1"
          /db_xref="GI:14247090"
/translation="MCTYSHYIEVERMSDKILENGSEIILNDSTSHRTNQSQIT
LSDYIRKLKLDKDLVQKNHNGTKIITSNVNNTILYLOQLHINLDDIIBIQKSVI
DSYFNKQKQSGSNYDTKLENRI"
gene      5807..6538
CDS       /gene="SAV1320"
          5807..6538
          /gene="SAV1320"
          /note="similar to ABC transporter integral membrane
protein"
          /codon_start=1
          /transl_table=11
          /product="hypothetical protein"
          /protein_id="BAB57482.1"
```

```
/db_xref="GI:14247091"
/translation="MILSYLKIIEFKVIMSKKTTLLSLPVPVIFVILFTSTYLELPEDV
KPKREKMSMTVYSLSSILTFPDLINSEKONERQRLMWPPTFTSYVSKVVK
TMQIQTALIVLWGYFYKGVMSAVOMLESCILNLCASLITFGLISLNDIOLK
ISALANIVTIGLAVGLGFWPFIITFPNLOHVAHVLPVSHLKRKLCVDTASNNHNLIS
FAILLVGLGSIIVICISHFHRAE"
gene      6542..7633
CDS       /gene="SAV1321"
          6542..7633
          /gene="SAV1321"
          /note="similar to two-component sensor histidine kinase"
          /codon_start=1
          /transl_table=11
          /product="hypothetical protein"
          /protein_id="BAB57483.1"
          /db_xref="GI:14247092"
/translation="MKELKSTAEISSTLYLFIPIAGIFNEVYGPKNLYLSIVVF
SUSYLLIVNRLNLMFLILLIRHFIICFVSEHMSLEFFFYSAFAVPTFKN
IAKRTATNLFTMICTITTYLLNNFYHVAWVYVYVLSLMLDNFKMKRREYKE
IAKRNHNTLIAGEOHRHIGQDLHDTLGHVAFASLCKSELAKLIDIDYERKAELE
AIKLSRESLNKVRREIIDDVKLPSFIEEISIRKVLKDDADIDFTFENKELAQVLSPTK
QSMLYMITREAINNVIRHANASVHGKLTNVNNHKLULLMIEDDGKIDSDCEVKSISO
RVQHLNGTLAVDSTNGTKIIIEISTGGIA"
gene      7630..8232
CDS       /gene="SAV1322"
          7630..8232
          /gene="SAV1322"
          /note="similar to two-component response regulator"
          /codon_start=1
          /transl_table=11
          /product="hypothetical protein"
          /protein_id="BAB57484.1"
          /db_xref="GI:14247093"
/translation="MSTUIIAEDONHLQAWQLIKLGDFFILADTNGLOAMKLE
EYNPVNIIDIEPMTGLEVAELERKHNRIKIVITIFRAGPTFEKAYVNDVAVY
SEKRSIEELVETPNKNGKEYSATLMTSFFVDKNAPLTPKQIOLVREINGLSREI
SEKLFUTDGTVRNYSYIIDKLFADNRFDANKKANEKGM"
gene      complement(8345..8533)
CDS       /gene="SAV1323"
          complement(8345..8533)
          /gene="SAV1323"
          /codon_start=1
          /transl_table=11
          /product="hypothetical protein"
          /protein_id="BAB57485.1"
          /db_xref="GI:14247094"
/translation="MNISNENTVLIAVIAIIGIFLQIFFKPLPLVITAVLSILLGI
FVGFTYVLIIVSYNKRKN"
gene      8672..9205
CDS       /gene="nuc"
          8672..9205
          /gene="nuc"
          /codon_start=1
          /transl_table=11
          /product="thermonuclease"
          /protein_id="BAB57486.1"
          /db_xref="GI:14247095"
Query Match 100.0%; Score 387; DB 1; Length 345900;
Best Local Similarity 100.0%; Pred. No. 1.2e-77;
Matches 387; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GATCTTCTCTCTTCCACCAAAATGAGAAACAACTGCATCTCTACCAAGTCCACCAAGCCTA 60
DB 200303 GATCTTCTCTCTTCCACCAAAATGAGAAACAACTGCATCTCTACCAAGTCCACCAAGCCTA 200362
QY 61 AACCATGTGACCTGATATCGGATCGGTTCCACCAATCCCTAATGAATAGAAATCATACA 120
DB 200363 AACCATGTGACCTGATATCGGATCGGTTCCACCAATCCCTAATGAATAGAAATCATACA 200422
QY 121 CGTCTGTACGCATTTCATATTATCTACTTTGTTAACCGCTTAATACGACCGGTTTTTTAG 180
|||||
```

Db 200423 CGTGTACGCAATTTCCATATATTCTACTTTGTTAACCGCTAATACGACGGTTTTTTAG 200482

Qy 181 ATTGTATAAAATTTGAGGACCAATTCATCGCTTTGTGCAATCCCTTCACGACGTTAA 240

Db 200483 ATTGTATAAAATTTGAGGACCAATTCATCGCTTTGTGCAATCCCTTCACGACGTTAA 200542

Qy 241 CCATPAATAAATAACATCGCTTCATCATCGGATTTCTGCGCTGCGCTCTAAATTTGTC 300

Db 200543 CCATPAATAAATAACATCGCTTCATCATCGGATTTCTGCGCTGCGCTCTAAATTTGTC 200602

Qy 301 TTTGGAATGTGTCATCACCACCAATTTCAATACCACTGTATCAATATATTGAATCATGTG 360

Db 200603 TTTGGAATGTGTCATCACCACCAATTTCAATACCACTGTATCAATATATTGAATCATGTG 200662

Qy 361 TTAACCATTCACCTGAAGATAAATAC 387

Db 200663 TTAACCATTCACCTGAAGATAAATAC 200689

RESULT 5

AF270032 3269 bp DNA linear BCT 01-AUG-2000

LOCUS Staphylococcus epidermidis strain SRI clone step.1042f07 genomic

DEFINITION sequence.

ACCESSION AF270032

VERSION AF270032.1 GI:9623936

KEYWORDS Staphylococcus epidermidis

SOURCE Staphylococcus epidermidis

ORGANISM Bacteria; Firmicutes; Bacillales; Staphylococcus.

REFERENCE 1 (bases 1 to 3269)

AUTHORS Kimmerly,W.J., Taylor,J.David., Nelsen,A.J., Godlevski,M.M., Rubino,M.A., Nelson,F.J., Rivers,P.R., Torruella-Miller,I., Listenbee,S., Ashanti,C., Altschuller,G., Mamo,L., Shepherd,N.S., Fuchs,R., Fleming,T., Guan,X., Du,L., Cain,D.H., Miller,G.S. and Furdon,P.J.

TITLE Transposon-mediated sequencing of the Staphylococcus epidermidis genome

JOURNAL Unpublished

REFERENCE 2 (bases 1 to 3269)

AUTHORS Taylor,J.David., Kimmerly,W.J., Nelsen,A.J., Godlevski,M.M., Rubino,M.A., Nelson,F.J., Rivers,P.R., Torruella-Miller,I., Listenbee,S., Ashanti,C., Altschuller,G., Mamo,L., Shepherd,N.S., Fuchs,R., Fleming,T., Guan,X., Du,L., Cain,D.H., Miller,G.S. and Furdon,P.J.

TITLE Direct Submission

JOURNAL Submitted (22-MAY-2000) Departments of Genomic Sciences and Bioinformatics, Genetics Directorate, Glaxo Wellcome, Inc., 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, USA

FEATURES

source

1. 3269

/organism="Staphylococcus epidermidis"

/mol\_type="genomic DNA"

/strain="SRI"

/db\_xref="taxon:1282"

/clone="step.1042f07"

BASE COUNT 985 a 616 c 451 g 1216 t

ORIGIN

Query Match 67.8% Score 262.2; DB 1; Length 3269;

Best Local Similarity 79.8%; Pred. No. 3.1e-49;

Matches 309; Conservative 0; Mismatches 78; Indels 0; Gaps 0;

Qy 1 GATCTCTCTCTTCACCAAAATGAGAAACAACTGCATCTAACAGTCCACCAAGACCTA 60

Db 2297 GATCTCTCTCTTCATTAAGATTTTCAACAACACTGCATCTAGCAAACTCTCCAAAGTCCTA 2356

Qy 61 AACCATGTGACCTCATATCGGATTCACCAAACTCCTAATGAATGAATCATACA 120

Db 2357 ATCCATGTGAACCAATAGGATATGATCTCCAAAGCTTAAGAATGAATCATAGA 2416

Qy 121 CGTCTGTACGCAATTTCCATATATCTACTTTGTAAACCGCTAATACGACGGTTTTTTAG 180

Db 2417 TATCATTACGCAATTTCAAGATTATCAACTTTTATTACAGCTAATACACAGGTTTCTTAG 2476

Qy 181 ATTGTATAAAATTTGAGGACCAATTCATCGCTTTGTGCAATCCCTTCACGACGTTAA 240

Db 2477 ATTGTATAAAATTTGAGGACCAATTCATCGCTTTGTGCAATCCCTTCACGACGTTAA 2536

Qy 241 CCATPAATAAATAACATCGCTTCATCATCGGATTTCTGCGCTGCGCTCTAAATTTGTC 300

Db 2537 CCATPAATAAATAACATCGCTTCATCATCGGATTTCTGCGCTGCGCTCTAAATTTGTC 2596

Qy 301 TTTGGAATGTGTCATCACCACCAATTTCAATACCACTGTATCAATATATTGAATCATGTG 360

Db 2597 TTTGGAATGTGTCATCACCACCAATTTCAATACCACTGTATCAATATATTGAATCATGTG 2656

Qy 361 TTAACCATTCACCTGAAGATAAATAC 387

Db 2657 TTAACCATTCACCTGAAGATAAATAC 2683

RESULT 6

AX145350 3269 bp DNA linear PAT 31-MAY-2001

LOCUS Sequence 4072 from Patent WO0134809.

DEFINITION

ACCESSION AX145350

VERSION AX145350.1 GI:14283915

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM artificial sequences.

REFERENCE 1

AUTHORS Kimmerly,W.J.

TITLE Staphylococcus epidermidis nucleic acids and proteins

JOURNAL Patent: WO 0134809-A 4072 17-MAY-2001;

GLAXO GROUP LIMITED (GB)

FEATURES

Location/Qualifiers

source

1. 3269

/organism="synthetic construct"

/mol\_type="genomic DNA"

/db\_xref="taxon:32630"

/note="synthetic nucleic acid sequence"

BASE COUNT 986 a 616 c 451 g 1216 t

ORIGIN

Query Match 67.8% Score 262.2; DB 6; Length 3269;

Best Local Similarity 79.8%; Pred. No. 3.1e-49;

Matches 309; Conservative 0; Mismatches 78; Indels 0; Gaps 0;

Qy 1 GATCTCTCTCTTCACCAAAATGAGAAACAACTGCATCTMACAAGTCACCAAGACCTA 60

Db 2297 GATCTCTCTCTTCATTAAGATTTTCAACAACACTGCATCTAGCAAACTCTCCAAAGTCCTA 2356

Qy 61 AACCATGTGACCTCATATCGGATTCACCAAACTCCTAATGAATGAATCATACA 120

Db 2357 ATCCATGTGAACCAAAATAGGATATGATCTCCAAAGCTTAAGAATGAATCATAGA 2416

Qy 121 CGTCTGTACGCAATTTCCATATATCTACTTTGTAAACCGCTAATACGACGGTTTTTTAG 180

Db 2417 TATCATTACGCAATTTCAAGATTATCAACTTTATTCACAGCTAATACACAGGTTTCTTAG 2476

Qy 181 ATTGTATAAAATTTGAGGACCAATTCATCGCTTTGTGCAATCCCTTCACGACGTTAA 240

Db 2477 ATTGTATAAAATTTGAGGACCAATTCATCGCTTTGTGCAATCCCTTCACGACGTTAA 2536

Qy 241 CCATPAATAAATAACATCGCTTCATCATCGGATTTCTGCGCTGCGCTCTAAATTTGTC 300

Db 2537 CCATPAATAAATAACATCGCTTCATCATCGGATTTCTGCGCTGCGCTCTAAATTTGTC 2596

Qy 301 TTTGGAATGTGTCATCACCACCAATTTCAATACCACTGTATCAATATATTGAATCATGTG 360

Db 2597 TTTGGAATGTGTCATCACCACCAATTTCAATACCACTGTATCAATATATTGAATCATGTG 2656

Qy 361 TTAACCATTCACCTGAAGATAAATAC 387

2657 TTAACCACTCGCCAGATCAATAATAC 2683

RESULT 7  
LOCUS AEO16747  
DEFINITION Staphylococcus epidermidis ATCC 12228, section 4 of 9 of the complete genome.  
ACCESSION AEO16747 AEO15929  
VERSION AEO16747.1 GI:27315369  
KEYWORDS  
SOURCE Staphylococcus epidermidis ATCC 12228  
ORGANISM Staphylococcus epidermidis ATCC 12228  
REFERENCE 1 (bases 1 to 300892)  
AUTHORS Zhang, Y., Ren, S., Li, H., Fu, G., Lu, L., Lu, G., Jia, J., Tu, Y., Qin, Z., Chen, Z. and Wen, Y.  
TITLE Direct Submission  
JOURNAL Submitted (05-NOV-2002) Chinese National Human Genome Center at Shanghai, 250 Bi Bo Road, Shanghai 201203, China  
FEATURES  
source  
1..300892  
/organism="Staphylococcus epidermidis ATCC 12228"  
/mol\_type="genomic DNA"  
/strain="ATCC 12228"  
/db\_xref="ATCC:12228"  
/db\_xref="taxon:176280"  
113..346  
/locus\_tag="SE0907"  
113..346  
/locus\_tag="SE0907"  
/codon\_start=1  
/transl\_table=11  
/product="acyl carrier protein"  
/protein\_id="AA004504.1"  
/db\_xref="GI:27315370"  
/translation="MENNFKYKQIIVDRGLGVADKYVEDASFKDGLGADSLDIAELVM  
ELEDFGFEIPDEAEKINTVGAATYNSLEK"  
461..1198  
/locus\_tag="SE0908"  
461..1198  
/locus\_tag="SE0908"  
/codon\_start=1  
/transl\_table=11  
/product="RNase III"  
/protein\_id="AA004505.1"  
/db\_xref="GI:27315371"  
/translation="MANQKKKEMVHNFQKFTDKMSLGLHFKNIDLYQQAFFSHSFI  
NDFNNRLEHRELFEGDGLVLEFVTSRYLFDRLPHLPNGNLTKNRATICEPSLVIF  
ANKIKNELILLGQKEKTGRTPSLISDAFEAFVGLYLDQGLDSVMTAEKVIPT  
VYEDDLGVVDFTQGEQYVHSGKNGDVTYQLIKEGPAHRLTTSVILENKA  
VGKGTKESEOKAAEQAYKLKNNKSL"  
1325..4894  
/locus\_tag="SE0909"  
1325..4894  
/locus\_tag="SE0909"  
/codon\_start=1  
/transl\_table=11  
/product="chromosome segregation SMC protein"  
/protein\_id="AA004506.1"  
/db\_xref="GI:27315372"  
/translation="MVYLSKSIDATGFKSPADHTNVQDGVTAIVPGNSGKSNITDA  
IKWVLEQGSASLGAQMEDIIFSGAHRKAQNFARVKKLNDNSHQKLIQISEELVTV  
RILYRSGESEYVLLNDRARMDIIDLFDLSGLGKEAFSIISQGRVDETLNAPKNRRQ  
IIEESAGVLYKKRKAESIKLQDHTDNLRVEDILYDLGEVPELPKEAAIAKEYKQ  
LSKMEQSDVTVTSDIDHTEDNRDLRNLKLSQAAKEGQQAQINOLLQYKYG  
ROONDYDIEKLYLVKATENYQDLSGLNVLEERKKNOSETNARVREELNLESQID  
STKNEAKNLLAELKNQKQNLKVEQLESLIYDSFQHDKEELKEEKNYVLTMSD  
QSDVNDIRLEHTINENAKSLDSRLVFAFNQKLDIQQITQITQYEQSSKKSHE  
KYEQNIQLEQSLDLSKRLSELNLIQAIRINEKLKSLDSLATQEETIYFNG  
KILKAKELURGLHGAIVNIPSEMTQAIETALSLQIHLVINDKDKQRAIYGL  
NRTIIVENKHAENKARIYKTRIVTLEGDVNPGSGMTGGARKTKILSKDELST

MRNLEDDYQRTAEFRKEQKTOAEOLSEQYFSASQOYVNNLKEOVHHHELELDRL  
TQEAHLNHEHEFEFKNDGYQSDKSETKLKEQKNHLIEIOOQLKQLESIDERTYLTLS  
KEGKASTHOTQOQLHQKQDLAVYKRIKSKQYERLDRKOLSDSERKQTEYVNEKIKL  
FNSDENMKDAFEKLKEQIQOQENVRQNLNQQOLSEIKQQRKDLNEKTEINSEQLQKCH  
ODILSINHHYQDIKAKQSLDVLINHAIDHLNDLTQVLTVERARMEYQSDDETIDNLRK  
VKTKTTHAQDQVHNNAIEQFEELNERYTTFUNORTDLREAKETLEKQKHLQKHSLE  
KRLTFTHAVQDHTVTFKOLFEGQQAELRLTEDDYLSAGVDIIVQPPGKHLQKHL  
SGGRGTAESDALLYFAILKYRSAPFVILDEVAALDEANVIRYAOYLNELSTETOFIV  
THRKTGTMEFSADRLLYVTMQESGVSKVLSVNLNTIDEVNMKEQA"  
4891..6117  
/locus\_tag="SE0910"  
4891..6117  
/locus\_tag="SE0910"  
/codon\_start=1  
/transl\_table=11  
/product="signal recognition particle"  
/protein\_id="AA004507.1"  
/db\_xref="GI:27315373"  
/translation="MSFFKRLKDKFESSKEDDIQKDLDETVDNSHANSDSMDPMNDSI  
EQVPRKPKKSLSEADDEDGLISDFEEIEAQKIGAKFKAGLEKSRQNFQOLNLL  
IARYKVDEDDFEALDEEMITADVGFNTVKNKLTQDLRTEAQRNRIQETDLREVIVK  
IVEIYHOEDDHSEAMNIEDRLNVILMYGVNGVGTQTTIGKLAYRYQDEGKKVYVLAAG  
DTFRAGAIOQLNYMGERVGVYVYVQNSQESDPAAYVYDAINAAKNKGVDILICDTAGRL  
QKNSNLNQELDKMKRVINRAIPDAPREALCLDATTGONALSQARSFKEFVNTVSGVIL  
TKLDGTAKGGIVLAIRNELHIPVYVGLGCKHMDQLQFPNPEPVYVGLFADMIQONEDI  
PEEISRSNVSVEEEN"  
6119..6451  
/locus\_tag="SE0911"  
6119..6451  
/locus\_tag="SE0911"  
/codon\_start=1  
/transl\_table=11  
/product="conserved hypothetical protein"  
/protein\_id="AA004508.1"  
/db\_xref="GI:27315374"  
/translation="MGONDLVYKTLRMNYLFDYQSLTNKOKNYLEFFYLDQYLSLSEI  
ADTEFVSRAVYDNIIRTDGOLVEDYESKRLRYQRFKRRREDYLNKMSLNQNPPELLKY  
ITOLEELE"  
6482..7849  
/locus\_tag="SE0912"  
6482..7849  
/locus\_tag="SE0912"  
/codon\_start=1  
/transl\_table=11  
/product="ffh protein"  
/protein\_id="AA004509.1"  
/db\_xref="GI:27315375"  
/translation="MAFEGLSDRLOATQKMRGKQVTEADIKTMREVRLLALBADY  
NFKYVKEFVTVSERALGSDVMQSLTPCQOYIKIIOBELTSLGCGTNTSKMKNPPT  
VMAVGLQGVKTAGKALLMRKYKPKLLVAGDIYPPAALDOLOTVKQKIDILEV  
YSEGDQSPQOIVENALKKXSEHLDFVIIDTAGELHIDEALHMLQEVKLEIKRDEI  
MLVYDATTGQAAVNAQSEDEGLDUSVTLKLSQDFAGANALSIKRTQNPINFGM  
SEKLDGUELFEPERMASTRILGAGDVLSELIAQODVQESKAKDLERKHSSTILOOF  
LEQLDQVKNLGLPDDIKRWIPKNNKAGLDLNKSDKQIDHINKAILOSMTPKERSNPE  
TLAVSRKKRIAKSGSRSLQEVNRLMKQFNDMMKKMKKQFTGGGKGGKAKAKRQNMNLK  
NLPF"  
8281..8556  
/locus\_tag="SE0913"  
8281..8556  
/locus\_tag="SE0913"  
/codon\_start=1  
/transl\_table=11  
/product="30S ribosomal protein S16"  
/protein\_id="AA004510.1"  
/db\_xref="GI:27315376"  
/translation="MAVKIRLRLGSKRNPFRYIVADARSPRGRIIEQLGTYNPAH  
VNAPEVVIDELALKWLDHCAKPTDTVHNILSREGILKKFDEQKNK"  
8683..9186  
/locus\_tag="SE0914"  
8683..9186  
/locus\_tag="SE0914"  
/codon\_start=1  
/transl\_table=11

```
/product="rlm protein"
/protein_id="AA004511.1"
/db_xref="GI:27315377"
/translat="MEVEGQIVNTHGKGEVVKNSDFTETRFQGEOLLVKHNNH
EIVTVASIRHGFHMLFEGINNIIEHLKDYIVQERHODIELGHEHYYSDI
IGTVFKDDPTIGRVINIFETGANDVMVYVKEKYLIPYIEDVVKDIDITATIN
PMBGLLD"
gene
9186..9923
/locus_tag="SE0915"
CDS
9186..9923
/locus_tag="SE0915"
/codon_start=1
/trans_table=1
/product="trna (guanine-ml)-methyltransferase"
/protein_id="AA004512.1"
/db_xref="GI:27315378"
/translat="MKIDYLTLPFEMFEGVLNHSILKRAQDKGIINVTINFRDYSIN
KHQVDYPPGCGQGVHLPPEVFNAMEDINNHETRVILMCPQGRFPTQZIAQELSE
AKHIVFCGHEGYDERIKRHLVDIISMGDYVLTGGELPANTWDIVRLIFVLGN
QASHQDSFDGLLEFPQYTRPREYKNMSVPEVLLSGNHAHIDQWRHEQKLIRYER
PDLEQVPLTEKDRILETYKKLND"
10029..10379
/locus_tag="SE0916"
CDS
10029..10379
/locus_tag="SE0916"
/codon_start=1
/trans_table=1
/product="50S ribosomal protein L19"
/protein_id="AA004513.1"
/db_xref="GI:27315379"
/translat="MSNHLIEAVTKSOLRTDLPTFRSGDTRVHVIRVEGSRERIQV
FSGVTKRRGGISEFTVTKRSSGVGERTPLTPRIEKIEVKRRGKVRRAKLYL
RSLGKAARTOEIR"
complement(10910..13513)
/locus_tag="SE0917"
CDS
complement(10910..13513)
/locus_tag="SE0917"
/codon_start=1
/trans_table=1
/product="conserved hypothetical protein"
/protein_id="AA004514.1"
/db_xref="GI:27315380"
/translat="MKNIANKPIRFTLVLVSCILSFLYQFTTKGIIVPSG
SGDFROMPFOMLHEFTISGDFSGGGDYVKSLAYIYSLPLMWINFSLIM
ILEQIVNPHDISFTINOLIMAYVTVITFISFLYSLRLKRPAMPTATILYGM
STVITYNTWSPYGNLLIMPLMSLWAIERFKRIGNFIFAYTLFNSFYFYE
AIVGIFYIRFAPHEKDIVNRWOKLYLVCAATLLSVLYGLYGVSGFLDNRT
ONPKITFTNFTNYIFADGFYITISFIALEFCFLYGHYVYKFAIATWIL
LIGFSQFDSAFSGSPQRWVFLALSTVLIALEFCFLYGHYVYKFAIATWIL
YGFIFALSERSVKMFVALIIVLFIKYSLLTSTSMVLLVYVFLAQVLT
NDSKITIEYOTTIKTINDSVSPVLNKKIKYMHOSSTDLPLKLDYPSYALNSPL
IYVNGTSLSYISFDGLKYDQTLQINPKVKNSTYRLNRSNKLMSLWDQDLR
HPDLNLPYFKKELITDKDQTHSVNTINYPKHITNKIDARKLKSPLREQM
LKGVNLNKSQANTDKPHNLLSNKONLHANNIDSKHLYKQHGGLVILNPLNI
VKYKDYIEMDVLLSPKHEKHYGVNEXSQERNLSYKTRFVSPVTKAKASNLQ
IKNSGVYRKYKGIIGENTQILKASQQLQPVKVKERNGTFTIKKKHGLVILPLM
YIACGMHANGKPLKVVQONGIMTIPVKGQTKIKLSYTPPYGLITVSCIGIIL
SILFTHVYKRR"
complement(13506..15779)
gene
Query Match 67.8% Score 262.2; DB 1; Length 300892;
Best Local Similarity 79.8% Pred. No. 2e-49;
Matches 309; Conservative 0; Mismatches 78; Indels 0; Gaps 0;
QY 1 GATCTCTCTCTCTTACCAAAATGAGAACTGCATCTAACAGTCCACCAAGCTTA 60
DB 296677 GATCTCTGATCTTATTAAAGTTTTCACAACTGCATCTAGCAATCTCAAGTCTCA 296735
QY 61 RACCATGTGACCTGATACGGATACGGTTCACCAAAATCTTAATGAATAGAAATCATACA 120
DB 296737 ATCCATGTGAACCAAGAAATAGGATATGGATCTCCAAAGCTTAAGAAATAGAAATCATAGA 296796
QY 121 GGTCTGTACCGAATTCATATCTACTTGTGTACCGCTAATACGACCGGTTTTTAG 180
```

```
Db 296797 TATCATACGACATTTCAAGATTATCAACTTATTATTCACACGCTAAATACACAGGTTCTTAG 296856
QY 181 ATTTGTATAAAATTTGAGCGACCATTCATTCCTCTGTGTCAATCCCTTCACGACGTTAA 240
Db 296857 ATTTATAAAGCATTTGTGCGACCATTTCTGCTCACTTTGTGTAAGTCTCTCTCAACATGA 296916
QY 241 CCATAAAATTAATCAATCGCTTCATCTATCGGCAATTTCTGCTGCGCTCTAATTTGTG 300
Db 296917 CCATAAAATTAATCAATCGCTTCCTTCAATTTCTGCTGCGCTGCGATTTGAG 296976
QY 301 TTTGGAATGTGTCATCACCACCAATTTCAATACCACCTGTATCAATATATTTGAATCATGTG 360
Db 296977 TTTGAAAGGAGCATCTCCAAATTTCAATACCACCTGTATCAATGTTAAATTCATGAG 297036
QY 361 TTAACCATTCACCTGAAGATAAATAC 387
Db 297037 TTAACCATTCGCGAGATGAATAAATAC 297063
RESULT 8
AE017028/c 290117 bp DNA linear BCT 30-APR-2003
LOCUS Bacillus anthracis str. Ames section 5 of 18 of the complete
DEFINITION genome.
ACCESSION AE017028 AE016879
VERSION AE017028.1 GI:30255149
KEYWORDS Bacillus anthracis str. Ames
SOURCE Bacillus anthracis str. Ames
ORGANISM Bacteria; Firmicutes; Bacilliales; Bacillaceae; Bacillus; Bacillus
cereus group.
REFERENCE 1 (bases 1 to 290117)
Read, T., Peterson, S., Tourasse, N., Baillie, L., Paulsen, I.,
Nelson, K., Tettelin, H., Fouts, D., Eisen, J., Gill, S., Holtzapple, E.,
Okstad, O., Helgason, E., Ristone, J., Wu, M., Kolonay, J., Beanan, M.,
Dodson, R., Brinkac, L., Gwinn, M., DeBoy, R., Madupu, R., Daugherty, S.,
Dukula, A., Haft, D., Nelson, W., Peterson, J., Pop, M., Khouri, H.,
Radtke, D., Benton, J., Mahamoud, Y., Jiang, L., Hance, I., Weidman, J.,
Berry, K., Plaut, R., Wolf, A., Watkins, K., Nierman, W., Hazen, A.,
Cline, R., Redmond, C., Thwaite, J., White, O., Salzberg, S.,
Thomas, B., Friedlander, A., Koehler, T., Hanna, P., Kolsto, A.-B. and
Fraser, C.
The genome sequence of Bacillus anthracis Ames and comparison to
closely related bacteria
Nature 423 (6935), 81-86 (2003)
JOURNAL MEDLINE 22608414
PUBMED 12721629
REFERENCE 2 (bases 1 to 290117)
Read, T., Peterson, S., Tourasse, N., Baillie, L., Paulsen, I.,
Nelson, K., Tettelin, H., Fouts, D., Eisen, J., Gill, S., Holtzapple, E.,
Okstad, O., Helgason, E., Ristone, J., Wu, M., Kolonay, J., Beanan, M.,
Dodson, R., Brinkac, L., Gwinn, M., DeBoy, R., Madupu, R., Daugherty, S.,
Dukula, A., Haft, D., Nelson, W., Peterson, J., Pop, M., Khouri, H.,
Radtke, D., Benton, J., Mahamoud, Y., Jiang, L., Hance, I., Weidman, J.,
Berry, K., Plaut, R., Wolf, A., Watkins, K., Nierman, W., Hazen, A.,
Cline, R., Redmond, C., Thwaite, J., White, O., Salzberg, S.,
Thomas, B., Friedlander, A., Koehler, T., Hanna, P., Kolsto, A.-B. and
Fraser, C.
Direct Submission
Submitted (26-MAR-2003) The Institute for Genomic Research, 9712
Medical Center Dr, Rockville, MD 20850, USA
JOURNAL MEDLINE 22608414
PUBMED 12721629
FEATURES
source
1. 290117
/organism="Bacillus anthracis str. Ames"
/mol_type="genomic DNA"
/db_xref="taxon:198094"
331..1929
/locus_tag="B1197"
331..1929
/locus_tag="B1197"
/notes="similar to GP:10717143, and GP:10717143;"
gene
CDS
```



```
identified by sequence similarity; putative"
/codon_start=1
/transl_table=11
/product="oligopeptide ABC transporter,
oligopeptide-binding protein"
/protein_id="AAP25159.1"
/db_xref="GI:30255150"
/translation="MNLGACSYOKDEPOANAKGDSKSGAKOVINTEVSEIPTMDTT
LAGDAASSVMNMTMEGLYRLGKDGKLVPGVAKSHTSKEDGKYTKFLKREDAKNSGD
PVTKDFVAMORAVNPDTAAKSGYIMLDVKNARKINKRELSPDLGKRAIDYDTEV
ELNDPVYFLDVTVPFLPELNEKYKGEQKFLGKNTLYLNGPVLNKRHEQSFQ
LKNPYNDOKEVKLEEVNFNVXDTGAAYNLXTSALDRVGLSALVDYKQCOQFK
TINDPVEFLRNQNPALANNIKALSSAYDRGGEVILNNGSGKAGLWPSDFY
KGDQKQFRENKSGKYDKAKAFNEAGKELGDKKIEIEFLNFEDESKKRIEYIV
KGLKELNGLVYTIKMQPFAOKLEDSGQDFISFTGMGPDPDAITFDMDPITDGS
QNMKGSNAYDSLIRKAKQEGSDVKGRNDLLKAEILFEDAAIAAPVFORGSILER
ETIKDYIHKYGEUSFKWAVEK"
/complement(1956..2099)
/locus_tag="BA1198"
/complement(1956..2099)
/locus_tag="BA1198"
/notes="identified by Glimmer2; putative"
/codon_start=1
/transl_table=11
/product="hypothetical protein"
/protein_id="AAP25160.1"
/db_xref="GI:30255151"
/translation="HIGVITNSIGKELFGGKKEKKFKVNSLDVOSGNEVGGIGIYKK
RTI"
gene
CDS
2731..3126
/locus_tag="BA1200"
/locus_tag="BA1200"
/notes="similar to SP:P32687, PID:409796, GB:U00096,
PID:1790459, SP:P32687, PID:409796, GB:U00096, and
PID:1790459; identified by sequence similarity; putative"
/codon_start=1
/transl_table=11
/product="conserved hypothetical protein"
/protein_id="AAP25161.1"
/db_xref="GI:30255152"
/translation="MYTLXSSPCTSCBKAKLHLEENHITYTERNIFSDPLTTEKE
ILMTSGGDEILSTRSKVQELNVLGSLPQDLKARDYPOILARPIMIDEKRLQ
VGVNEIRRPPIRVITFQLREARLVN"
complement(3176..3850)
/locus_tag="BA1201"
complement(3176..3850)
/locus_tag="BA1201"
/notes="identified by match to PFAM protein family HMM
PF03772"
/codon_start=1
/transl_table=11
/product="membrane protein, putative"
/protein_id="AAP25162.1"
/db_xref="GI:30255153"
/translation="MDLEFLTSLVMIIVGVVGGDNAIVTALASRLPESKRNAIL
IGTLALVRLIILTVLLVLLDIPQLIGGVLLTLVNLVLTDSNGLSSIOGKTL
FOAVRIVADLVMGFDNVIATAGAHGRESLVIGLISIPILNKSLLILMKERF
PFLIXGAILATAGKAWTHEDRLATEFHNNPSETAGIFLFIITLICIGFVQQR
LRVXKH"
4112..4210
/locus_tag="BA1202"
4112..4210
/locus_tag="BA1202"
/notes="identified by Glimmer2; putative"
/codon_start=1
/transl_table=11
/product="hypothetical protein"
/protein_id="AAP25163.1"
/db_xref="GI:30255154"
/translation="MICHMSGESLHNSKQEGRVVFWILKELMIIR"
4207..4860
/gene="meca"

identified by sequence similarity; putative"
/codon_start=1
/transl_table=11
/product="negative regulator of competence Meca"
/protein_id="AAP25164.1"
/db_xref="GI:30255155"
/translation="MKFFITYIDIEDRGFNREEIYDRENSEELFEMMDEARDHDDF
FIDGPLMIOVAVDGVIEVLTAKLSKQCKLPIGVDKIIDIPLDGSGISLFOQE
LVEVEEQAGTFNEDGTGFLINFDPEOVISLHRLIFEDIKDELYSFEDRYVYV
EFDEVLDDEEIDRLISLVLEYGEESTLTHRVSEYCKQIVKEHALETIRNFPART"
4933..6477
/gene="cls-2"
/locus_tag="BA1204"
4933..6477
/gene="cls-2"
/locus_tag="BA1204"
/notes="similar to SP:O66043, SP:O66043, SP:O66043,
SP:O66043, SP:O66043, and SP:O66043; identified by
sequence similarity; putative"
/codon_start=1
/transl_table=11
/product="cardiolipin synthetase"
/protein_id="AAP25165.1"
/db_xref="GI:30255156"
/translation="MKNTPLKLIFFVLLLFALFVSLRMFIDVAFYSVIGIKOVISILGI
ISILFTVSALFICGVIFLENRHPKTLTHLVILGIFPVFGFFAYLLFGONFRKRMFO
KKALDEQAFLOYKGHEDYEEIRILNRHKKHOELLFRLDRLGALNSVFOETRTLTNGO
ETFOATLQGLKRAKHIMYEYIVRDKLQTEIKDLOKSGEVVVRVLYDVGSEFK
LSKSYIEELNDAGVEMIPFPVREPILNDKINYNHRKTVIDNGEVFGVGLNIGDEY
LGKDYVGEFWRDTHLYLRGEAVOSQLIFLDQWFMNTGAVLAPEYLOAKAVEGEMHG
GYOLVAGGPDNKKWTIKHLYFAMIASARKSIHIATPYFPDDDLISALAAALCIDV
RLMPSKPDRTVFAVSRYFPELLDAGVKIYEYKGLHRSVWIVDSPLASIGTANM
DMRSHLFNEVNAFLYDTSIRKLVDQKDDLESSEIHWDRFKRLRRIVESTYR
LISPLL"
6559..7803
/locus_tag="BA1205"
6559..7803
/locus_tag="BA1205"
/notes="identified by Glimmer2; putative"
/codon_start=1
/transl_table=11
/product="conserved hypothetical protein"
/protein_id="AAP25166.1"
/db_xref="GI:30255157"
/translation="MIPFIARKENGKIHLLDHDPELLHMKRESPECIACCKEY
LMRLCKQKEMHFAHKVDSCLAFVASTVYMKGKLLYRNFKRONVHVEIHYLPEI
QORPOIFERAGRKTAIEYQCANLSIEQLCKRTYSIHWAGIQVINIIGNQUNKNSAY
WKFSIMAFSLQSTPQLLIFCSCKSEMKCTFITFSSTISAFSHIYLPDIETTF
EMLPSPVPFQEVLRKWRKRDYFQNALPILNKLRLCYCKCKNANFPFSEI
GVPLPSSFAFQTNISFIWQAFIHKICIGELAVGICISLYKVCYIKKYKRRMLPVFSQ
HIKWAVTEYMTFLCYAGLYKVGMYTYRIRDAVPLKTTGGGSIINKHDEICLAHALSLF
```

```

EAKFNRRGKGKDIIKTREGII*
7854..9580
/feature="pepf-1"

Query Match      54.4%; Score 210.6; DB 1; Length 290117;
Best Local Similarity 71.7%; Pred. No. 9.2e-38;
Matches 276; Conservative 0; Mismatches 109; Indels 0; Gaps 0;

OY 3 TCTTCTCTCTCTCACCACCAATGAGAACAACTGCATCTACAGTACACCAAGACCTATA 62
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280879 TCTTCTCTCAATCTTTGGAANAATGCTGCGACGCTCATCTATAAGTACCTCATCTAAT 280820

OY 63 CCAATGACCCGATATCGGATACGATCGGTTCCACCAATCTTAATGAATAGAAATCATACAG 122
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280819 CCGTGTGATCCGATGATGCGAATGCGTCCGCAATCTTAATGATAGAAATCATATAATG 280750

OY 123 TCTGTACGCAATTTCCATATTTACTTCTTGTTAACCGCTAATACGACCGGTTTTTATGAT 182
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280759 TCACGTGCGATTTCCGATTTGTCACCTTTATTTACTGCAAGTACAACCTGTTTATTGAA 280700

OY 183 TTGTATATAAATTTGACGACCACTTTCATCGCTTTGTGTCAATCCTTCACGACGTTAAC 242
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280699 CGATATAATATTTTGCACCTTCTTCATCCGCTGCTGTACACGCTACGACCACTTGT 280640

OY 243 ATAAATATATACATCCGCTTCATCTATGCGGATTTCTGCTCGGCTCAATTTGTGTT 302
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280639 ATAAATATATACATCTCTCTCAATCAATGCTACTTCTGCTGCTTTCACGCAATTTGTC 280580

OY 303 TGGATGTTGATCACCACCAATTTCAATACCACTGATCATCAATTAATTAATCATGTT 362
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280579 AAAATGGTCTGCTCTCAATATCAATCACTGATCATCAATTAATTAATCATGTT 280520

OY 363 AACCATTCACCTGAAGAATAATAC 387
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB 280519 AACCATTCACGCTGCTATAAATAC 280495

RESULT 9
AEO17002/c 304680 bp DNA linear BCT 16-MAY-2003
LOCUS Bacillus cereus ATCC 14579 section 5 of 18 of the complete genome.
DEFINITION Bacillus cereus ATCC 14579 section 5 of 18 of the complete genome.
ACCESSION AEO17002 AEO18877
VERSION AEO17002.1 GI:29894935
KEYWORDS
SOURCE Bacillus cereus ATCC 14579
ORGANISM Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus; Bacillus cereus group.
REFERENCE 1 (bases 1 to 304680)
AUTHORS Ivanova,N., Sorokin,A., Anderson,I., Galleron,N., Candelon,B., Kapatal,V., Bhattacharyya,A., Reznik,G., Mikhailova,N., Lapidus,A., Chu,L., Razur,M., Goltsman,E., Larsen,N., D'Souza,M., Walunas,R., Grechkin,Y., Pusch,G., Haselkorn,R., Fonstein,M., Ehrlich,D.S.D., Overbeek,R. and Kyrpides,N.
TITLE Genome sequence of Bacillus cereus and comparative analysis with Bacillus anthracis
JOURNAL Nature 423 (6935), 87-91 (2003)
MEDLINE 22608415
PUBMED 12721630
REFERENCE 2 (bases 1 to 304680)
AUTHORS Candelon,B., Gailloux,K., Ehrlich,D.S. and Sorokin,A.
TITLE The number of ribosomal RNA operons in Bacillus cereus
JOURNAL Unpublished
REFERENCE 3 (bases 1 to 304680)
AUTHORS Ivanova,N., Sorokin,A., Anderson,I., Galleron,N., Candelon,B., Kapatal,V., Bhattacharyya,A., Reznik,G., Mikhailova,N., Lapidus,A., Chu,L., Razur,M., Goltsman,E., Larsen,N., D'Souza,M., Walunas,R., Grechkin,Y., Pusch,G., Haselkorn,R., Fonstein,M., Ehrlich,D.S.D., Overbeek,R. and Kyrpides,N.
TITLE Direct Submission
JOURNAL Submitted (12-MAR-2003) INRA, Genetique Microbienne, Domaine de Vilvert, Jouy en Josas 78352, France
FEATURES
1..304680
/organism="Bacillus cereus ATCC 14579"
/mol_type="genomic DNA"
/strain="ATCC 14579"
/db_xref="ATCC:14579"
/db_xref="Caxon:226900"
58..427
/locus_tag="BC1239"
58..427
/locus_tag="BC1239"
/codon_start=1
/transl_table=11
/product="Hypothetical Membrane Spanning Protein"
/protein_id="AAP08224.1"
/db_xref="GI:29894936"
/translacion="MLRRKLLYFLVPLVYAMLSMTKIELMALEFLGVFIIFSNNRI
QSQSLKLEISLSEISLSEISVILLNELFLRHSFTLMKFNIILOAICTYIVFVVL
KRIVGKVQVFDNRKE"
551..2041
/locus_tag="BC1240"
551..2041
/locus_tag="BC1240"
/codon_start=1
/transl_table=11
/product="L-lactate permease"
/protein_id="AAP08225.1"
/db_xref="GI:29894937"
/translacion="MLALIPIMHIFICLFKQTSRSLRSYISVAVSGVILSPFQ
LGMFVHATIGWLCITGVYVLFEGIFLFLNNKMGYIDQVARELEEVTDRLQHL
LMCGICPLIESVSGFGIGFVMAAPFSLGYPQAVLLSFLGLASWGMATGTI
IGSOLINPLTLATNTALLISIPMAFVLSLVHVGQHVAVIEKMKSCVGFLLFSL
GYLNAVSVELAGLISIVITTFGLIKKXGCONLITEHAAATEREVSIIKI
SVYIELTVCLLSRLPALHDLFRSAVALDLKSYKLELLYSPGFMGTCLFTIF
FRIPNIKQSLQSIKOWIPATTTMTFATISLMAAGSMHSLKATAGDTFTFV
FVAPFAGIGGLTGSNAGSAFETKLOMOTAOVALPHOYVTTLQNTASSVATLAC
SRITLGAVLCNIPYRENELEKKTTLTIFGAVLLVVEVIVMYMLRN"
2132..2818
/locus_tag="BC1241"
2132..2818
/locus_tag="BC1241"
/codon_start=1
/transl_table=11
/product="Hypothetical protein"
/protein_id="AAP08226.1"
/db_xref="GI:29894938"
/translacion="MTLKNYGLKGTQVIOSEICKGKTPHYQVHLOCTGVYRTAIN
KQSYSPSEVLYFASNNTKSEAIHILPTLPGFTTEIKNNPKVADYIRGNLFDNOMI
PLPPEKAGADNDLNEKTERYTKRAIEKAIIVAFGERMGPEENTPDSYFHPKPGNHI
DIRHMQGVNKKVQGGDGTWQDGLIHFEKEEMIGIFLAFQSQSNCTDEBGRVPV
EMCDYKGNIK"
complement(2830..3663)
/locus_tag="BC1242"
complement(2830..3663)
/locus_tag="BC1242"
/codon_start=1
/transl_table=11
/product="Integral membrane protein"
/protein_id="AAP08227.1"
/db_xref="GI:29894939"
/translacion="MELVNSIFOLLTSVIQLSLIGVIVIGFLGLYLESIRMYNS
RAFGRKGLLTAWGVPTRHELGHAICMVLFRHKIVATQFPPTDSQALGYVQHOYNO
KSVYORIGNFGIGPIISGTLTLLIMRYEVSYLENTLTKTSTIMEMIO
NMLSTFVLLKSLFTICNLNAPSFLFELFICISAHIALSPDKNGSDGVIMFV
LEFLNIITGLFOYDSNOLIGOVKMYNMYLAFSSVALLFSCISTLVSFSFYAIRGRS
F"
3860..4630
/locus_tag="BC1243"
3860..4630
/locus_tag="BC1243"
/codon_start=1
/transl_table=11
/product="Hypothetical protein"
/protein_id="AAP08228.1"

```







Kurapkai, G., Madueno, E., Maitournam, A., Vicente, J. M., Ng, E., Medjari, H., Nordsiek, G., Novella, S., de Pablo, B., Perez-Diaz, J. C., Purcell, R., Remmel, B., Rose, M., Schlueter, T., Smoes, N., Tierrez, A., Vazquez-Boland, J. A., Voss, H., Wehland, J., and Cossart, P. Comparative genomics of *Listeria species* Science 294 (5543), 849-852 (2001)

21537279  
11679669  
2 (bases 1 to 347050)  
Glaser, P., Frangeul, L. and Rusniok, C.  
Direct Submission  
Submitted (06-JUN-2001) Glaser P., Institut Pasteur, Genomique des Microorganismes Pathogenes, 25 rue du Docteur Roux, 75724 Paris Cedex 15, FRANCE  
E-mail: pglaser@pasteur.fr  
Phone: +33 1 45 68 89 96, Fax: +33 (0)1 45 68 87 85.  
Location/Qualifiers  
1. 347050  
/organism="Listeria monocytogenes"  
/mol\_type="genomic DNA"  
/strain="EGD-e"  
/db\_xref="taxon:1639"  
complement(95..841)  
/gene="lmo1688"  
complement(95..841)  
/gene="lmo1688"  
/note="similar to glucose 1-dehydrogenase"  
/codon\_start=1  
/transl\_table=11  
/protein\_id="CAC99766.1"  
/db\_xref="GI:16411142"  
/db\_xref="SPTREMBL:Q8Y6J5"  
/translation="MKVAVLTGSSRGRLGRTAIALAKEGVDIANFSNRKKAEEVQ  
QEIQLRKGVIPKANGVDEKRELFRAYDEFGRLDIFINNAASGLVPLPLMELES  
HWDTHMINAKLLFQGAQAKMLQHRGSKLIISUSSIGSYILENTYTVGVSKAAVE  
SLRIYLAPEAGPIANAVSGLIETDNLHPRELLKDAVSKTPAGRMIEPNDL  
NVAVLASAKMIRGQITLVGGRTLLV"  
complement(join(845..1942,1948..1953))  
/gene="lmo1689"  
complement(845..1942)  
/gene="lmo1689"  
/note="similar to A/G-specific adenine glycosylase"  
/codon\_start=1  
/transl\_table=11  
/protein\_id="CAC99767.1"  
/db\_xref="GI:16411143"  
/db\_xref="SPTREMBL:Q8Y6J5"  
/translation="MRKMRLLWDEKKTAFQALVSYWEANKRVLPWRENTPEYRIW  
VSEIMQATYDVIVPIFNFMTPFTHESEFVNADEADILKANEGLYYSRVRLQTA  
MKQVADFSGEVTDUTLILSLGVPYPAGAILSIAYNOAEPADGVGNVRIARVLE  
IGEDIMRASTRKIFEEVLQIDKKNPAFNOGLMEIGALVCTPTKPMCLCPLOPFC  
EAKNGVETPYKIKKVKTKLELLSIIVSEDKIAIEKRPENGLLANWQFPPIE  
ISKREDAVAKLQFLHNYGLEVLLEDEPIAHIKHVFSLVWKMDIRVAKLQSAIPNEN  
WYFATEEMKRLAFPPYQKMQANKDKGE"  
complement(850..855)  
/gene="lmo1688"  
complement(850..855)  
/gene="lmo1688"  
complement(1948..1953)  
/gene="lmo1689"  
join(2129..3123,3130..3147)  
/gene="lmo1690"  
2129..2134  
/gene="lmo1690"  
2143..3123  
/note="similar to hypothetical proteins"  
/codon\_start=1  
/transl\_table=11  
/protein\_id="CAC99768.1"  
/db\_xref="GI:16411144"  
/db\_xref="SPTREMBL:Q8Y6J4"  
/translation="MDTGTTHVVGIALGALATVDPVVGSSQAIGINTAIIIGSOIP

DIDTVLKKKNADYIRNHRGITHSLPMLAIWPLLISSILYLLFPATFTIHLMLTPIA  
VGLHVFIDYVNAIGTQAVRPFKMTVAFGTFINDFWFIHSHVVAIAAHLGSPVLPT  
FVTLVLYLYVAREVTFKMTKHAVONLIPDSEIIIASTIHFQWRVATTKOHYY  
VGFARNTSIYKFORLPVDPDNEIRSAKDKNLAAAFSESKYNNRPIEEKLDGTIV  
TFIDLRYNSGHYFVAVVVKDDDLKIVSYSTGTFSTFKLYKKLAPVSI"  
complement(join(3130..3147,3156..3617,3625..3630))  
/gene="lmo1691"  
3130..3147  
/gene="lmo1690"  
complement(3130..3147)  
/gene="lmo1691"  
complement(3156..3617)  
/gene="lmo1691"  
/note="similar to deoxyuridine triphosphate  
nucleotidohydrolases"  
/codon\_start=1  
/transl\_table=11  
/protein\_id="CAC99769.1"  
/db\_xref="GI:16411145"  
/db\_xref="SPTREMBL:Q8Y6J3"  
/translation="MKVRGEVYNENASRRKFPQETISLPIRDGKSGAGYDFSNVTYI  
VPGEKHIFMTDIKSYMOEDVLNIVVRSSIGIKKGLLCLNCTGIIDSSYVSNPDNGN  
IGIAIKNFSPVSTEAGERVAGVQVFOKLYLVADTDIVANESRVGGVSGTGR"  
complement(3625..3630)  
/gene="lmo1691"  
complement(3629..3862)  
/gene="lmo1692"  
complement(3629..3862)  
/gene="lmo1692"  
/codon\_start=1  
/transl\_table=11  
/protein\_id="CAC99770.1"  
/db\_xref="GI:16411146"  
/db\_xref="SPTREMBL:Q8Y6J2"  
/translation="MYTLDLTAELMVKNPHLDKEQALMWIHLMSDFESSYAKAGY  
PYRGVADYVYRQQTIERHSGFLHOVERKDPNK"  
complement(join(3864..4673,4680..4685))  
/gene="lmo1693"  
complement(3864..4673)  
/gene="lmo1693"  
/note="similar to hypothetical proteins"  
/codon\_start=1  
/transl\_table=11  
/protein\_id="CAC99771.1"  
/db\_xref="GI:16411147"  
/db\_xref="SPTREMBL:Q8Y6J1"  
/translation="MKITSIVQKKNKERYNIFIDEKYNFSVDVEVLARYQLMKKRVL  
TEADIEIQADQVVRKGLNKAINFSLHVRSEKIRDYLRKQMEPFAIDEILKKLAN  
MDYINDEFAELYTQIKTLKGPRIERELVEKGTREIISRVIEEYSDAQLENA  
TKOAMKIMRNKSKAKMLQOKIITDLOKGTSELAKAAATSELDVDADEAELQ  
KOIEKTMKNNKPKSIKAKQITITSLMQKGSYDTIQSLTENEISFELEE"  
complement(3872..3877)  
/gene="lmo1692"  
complement(3872..3877)  
/gene="lmo1692"  
complement(4680..4685)  
/gene="lmo1693"  
join(4757..5673,5681..5708)  
/gene="lmo1694"  
4757..4762  
/gene="lmo1694"  
4771..5673  
/gene="lmo1694"  
/note="similar to CDP-abequose synthase"  
/codon\_start=1  
/transl\_table=11  
/protein\_id="CAC99772.1"  
/db\_xref="GI:16411148"  
/db\_xref="SPTREMBL:Q8Y6J0"  
/translation="WHILTCATGFIGDHLVHELEKSDHELYTLTRQKLNKNRNVHYI  
EMLNDEKLDLPVOCINLAGAGLMDKWTYDRKKVIVNSRIEATSAALLSVKKH  
KSKPKLWINASIGATVTSKTSIYDTEENTYADNFKGTIVYEMKTAASADLGIRV  
VYARFGLVLGTNGSGFPVFEKLFQTYTGGRFGNGRWYSHVHVDVVAAILFIDFHEQ

INGVNFETAPHPVOEKFABRGLKMKHKKPYKTPVPPKKIKFILGBRAMTILDSQRAYP  
EXLMSHFEFFFEFLOALDLDLD  
5681..5708  
/gene="lmo1694"  
/complement(5682..8291,8299..8304))  
/gene="lmo1695"  
/complement(5682..5709)  
/gene="lmo1695"  
/complement(5694..8291)  
/gene="lmo1695"  
/note="similar to putative membrane proteins"  
/codon\_start=1  
/transl\_table=1  
/protein\_id="CAC99773.1"  
/db\_xref="gi:16411149"  
/db\_xref="sptrembl:Q8Y619"  
/translation="MKELMQAVANFQKSTVVKVIFVFNAPVIFRINIATGIDY  
PSLKNIGTSQPEQIFTFMFIYGLIAVTPLMIDYIVVLLPKGSPSHVSIASGHTT  
FTNIGFCGVGLASLRASFYGNASHKEILLALSKALFLVSLGSIYCLVSLATLLIP  
GFADHFVNPMMLAGGLYPLIFLTITTKKSKSLFVDPPIKRELTLLIASLLENGFAP  
GCEAFTGLMGEVDIFKVPFLFVIAVIGIAGMPPGVGTEVDVNMILGSLQGVSOE  
LALAWMLFRIIFYIIPVVGLLFFVQKAGKKNDFLEGLPLFLKQVAHRELVIFY  
CSGULLLSSAVPNAIIVHFLFKIAPFNFLFSQITIVAFGLLGLARGLECKTKK  
AIIIVYIGCAFIENILARVFSKMAIFGLIVLLCLFLARNEFYREKLVITMYSKVID  
SIIFIVLKLAVIGITNPNIRKSKSEIPDYLRASEHLMVLGVFVGVFIAYVSVIY  
IYLSITKLEKTSPEAVKVRHAKMGNEVSHTEFLRDLKLLFAAEVLEFVSRIIA  
DKMVFQNTGMDGKKKGERALMKNKLEREGYFEIIEPPFNHDTWTLIRAVSDKLD  
EKGFDVSLGFLFTYLEQAPIAIAKNGEITVGFASMMPSYTOEMTIDLMRYSKEA  
PSGINDFLFLFEKAKEDGTFOTFNAGMAPLANVGSKVAFGLERGLAVLYRSOGY  
GFKGLRNFKSKYVTEMEQKVFVAFKRSSIAFTMLQMLILVGLKRLANSQVVLDEPLE  
EETKKPDSE"  
/complement(8299..8304)  
/gene="lmo1695"  
/complement(8318..9007)  
/gene="lmo1696"  
/complement(8318..8992)  
/gene="lmo1696"

Query Match 53.2% Score 205.8; DB 1; Length 347050;  
Best Local Similarity 70.9%; Pred. No. 1.1e-36;  
Matches 273; Conservative 0; Mismatches 112; Indels 0; Gaps 0;  
QY 3 TCTTCTTCTCTTCCACCAAAATGAGAAACAACTGCATCTAACAAAGTCACCAAGACCTAAA 62  
DB 258933 TCCTCTCTCTCTTTTGGAAAATGAGCGGAACGATCAAGCATGTGCGCAAGCCCTAGT 258992  
QY 63 CCATGTGACCCGTATCGGATACGGTTCCACCAATCCTTAATGATAGAAATCATACAGC 122  
DB 258993 CCATGTGACCAAGAAATGGATACGGCTCACCACCAAGCAAGATTAAGTCATAATT 259052  
QY 123 TCTGTACGATTCATATCTACTTTGTACCGCTTANTACGACCGGTTTTTTAGAT 182  
DB 259053 TGATCTCGATTTCTGGGTTATCTACTTTATATCGCTAAAACAATTTGTTATTAGAC 259112  
QY 183 TTGTATAAATTTGAGCACCATTTCATCGCTTTGTGTCAATCCTTCACGACCGTTAACC 242  
DB 259113 CGGTAAGAATTTTGTCTACTTGTCTGCTCGATCGGTAACTACTCTCAGCACCATTGTA 259172  
QY 243 ATAAAAATTAATCAATCCGCTTCTATCGGATTTCTGCGCTGCGCTCTAATTTGTT 302  
DB 259173 ATAAAAATTAATCGCTCTCTTCAATCAATTCGATTTCCGCTTGTGCGGAAATTTGCTCT 259232  
QY 303 TGGAAATGTCATCACCATTTCATACACCGCTGTATCAATTAATTAATTAATTCATGTT 362  
DB 259233 AAAATGTTTCTCGGAAGATCAATACACCGCTGTATCAATTAATTAATTAATTCATGTT 259292  
QY 363 AACCATTCACCTGAAGAATAAATAC 387  
DB 259293 AGCCATTCGCTGAATATATATGC 259317

RESULT 13

AX417046  
LOCUS 349980 bp DNA linear PAT 02-SEP-2002  
DEFINITION Sequence 4037 from Patent WO0228891.  
ACCESSION AX417046  
VERSION AX417046.1 GI:21449656  
KEYWORDS Listeria innocua  
SOURCE Listeria innocua  
ORGANISM Bacteria; Firmicutes; Bacilliales; Listeriaceae; Listeria.  
REFERENCE 1  
AUTHORS Kunst, F. and Glaser, P.  
TITLES Listeria innocua, genome and applications  
JOURNAL Patent: WO 0228891-A 4037 11-APR-2002;  
INSTITUT PASTEUR (FR); CENTRE NATIONAL DE LA RECHERCHE  
SCIENTIFIQUE (CNRS) (FR)  
FEATURES  
Location/Qualifiers  
1. 349980  
/organism="Listeria innocua"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:1642"  
/note="seq 2058 original length: 3.011.208 replaced  
by-seq 2038: 0.000.001 to 0.349.980-seq 4032: 0.300.001 to  
0.649.980-seq 4033: 0.600.001 to 0.949.980-seq 4034:  
0.900.001 to 1.249.980-seq 4035: 1.200.001 to  
1.549.980-seq 4036: 1.500.001 to 1.849.980-seq 4037:  
1.800.001 to 2.149.980-seq 4038: 2.100.001 to  
2.449.980-seq 4039: 2.400.001 to 2.749.980-seq 4040:  
2.700.001 to 3.049.980-seq 4041: 3.000.001 to 3.011.208"  
BASE COUNT 101055 a 72969 c 50688 g 115268 t  
ORIGIN  
Query Match 53.2% Score 205.8; DB 6; Length 349980;  
Best Local Similarity 70.9%; Pred. No. 1.1e-36;  
Matches 273; Conservative 0; Mismatches 112; Indels 0; Gaps 0;  
QY 3 TCTTCTTCTCTTCCACCAAAATGAGAAACAACTGCATCTAACAAAGTCACCAAGACCTAAA 62  
DB 266305 TCCTCTCTCTCTTTTGGAAAATGAGCGGAACGATCAAGCATGTGCGCAAGCCCTAGT 266364  
QY 63 CCATGTGACCCGTATCGGATACGGTTCCACCAATCCTTAATGATAGAAATCATACAGC 122  
DB 266365 CCATGAGAACCAAGAAATGGATACGGCTCACCACCAAGCAAGATTAAGTCATAATC 266424  
QY 123 TCTGTACGATTCATATCTACTTTGTACCGCTTANTACGACCGGTTTTTTAGAT 182  
DB 266425 TGATCTCGATTTCTGGGTTATCTACTTTATTAATCGCTAAAACAATTTGTTATTAGAC 266484  
QY 183 TTGTATAAATTTGAGCACCATTTCATCGCTTTGTGTCAATCCTTCACGACCGTTAACC 242  
DB 266485 CGGTAAGAATTTTGTCTACTTGTCTGCTGATCGGTAACTCTCAGCACCATTGGTA 266544  
QY 243 ATAAAAATTAATCAATCCGCTTCTATCGGCGATTTCTGCGCTGCGCTCTAATTTGTT 302  
DB 266545 ATAAAAATTAATTAGCTGCTGCTTCATCAATTTGCGCTTTGCGCGAAATTTGCTCT 266604  
QY 303 TGGAAATGTCATCACCATTTCATACACCGCTGTATCAATTAATTAATTAATTCATGTT 362  
DB 266605 AAGAATGTTCTGTCGGAAGATCAATACACCGCTGTATCAATTAATTAATTCATGTT 266664  
QY 363 AACCATTCACCTGAAGAATAAATAC 387  
DB 266665 AGCCATTCGCTGAATATATATGC 266689  
RESULT 14  
AX641670  
LOCUS 349980 bp DNA linear PAT 21-FEB-2003  
DEFINITION Sequence 2860 from Patent WO0101118.  
ACCESSION AX641670  
VERSION AX641670.1 GI:28474431  
KEYWORDS Listeria monocytogenes  
SOURCE Listeria monocytogenes  
ORGANISM







Db 21432 CGCTTCATCCATGGCGATTTCAGCTTGCTGGCGAATCTGCGCTAAACGGGCTCATCACC 21373  
 QY 320 AATTTCATACCCACCTGTATCATATATTTGAATCATGTGTAAACCATTCACCTGAAGA 379  
 Db 21372 GATATCATATACCGCCCGTATCAATCAATTAATAATTAATTCAGCCATTGAGCCGAGCT 21313  
 QY 380 ATAAATAC 387  
 Db 21312 GTATATCC 21305

Search completed: September 12, 2003, 19:27:28  
 Job time : 1589.02 secs